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Abstract 
Background: High-flow nasal cannula oxygen (HFNC) is a non-invasive alternative 
to nasal continuous positive pressure oxygen (CPAP) therapy for infants and 
children requiring respiratory support. There is a paucity of literature to support its 
use in children, with no published data from sub-Saharan Africa. 
Objective: To describe the outcomes and adverse events of HFNC in the first year of 
its use in a level two (L2) general paediatric ward, compared with outcomes of a 
historical cohort when this intervention was unavailable. 
Methods: This retrospective descriptive study included children aged <13 years who 
received HFNC in the first 12 months after its introduction (HFNC-availability group; 
n=66). Demographic data, clinical characteristics, and outcomes (death, treatment 
failure, length of HFNC, and HFNC-related adverse events) were assessed. A 
comparative description of children that required transfer to level 3 (L3) for 
respiratory support (more than available standard low-flow oxygen) in the 12-month 
period prior to HFNC availability (pre-HFNC group; n=54) was performed and 
outcomes were compared using standard descriptive and comparative statistics. 
Results:	The median age of the cohort was 5 months (interquartile range [IQR] 1.9–
14.6). Sixteen children (13.3%) were malnourished, 10 (8%) were HIV infected, and 
30 (25%) were ex-premature infants. The most common diagnoses were 
pneumonia, bronchiolitis, and asthma. Asthma, anaemia, and cardiac abnormalities 
were the most prevalent underlying co-morbidities. Two children died in each group. 
All 54 children in the pre-HFNC group were transferred to L3; 38 (70.4%) needed 
CPAP or invasive ventilation. In the HFNC-availability period, 85 children were 
assessed as needing more than standard low-flow oxygen therapy: 19 were 
immediately transferred to L3 where 17 (89.4%) received CPAP or invasive 
ventilation; 66 received HFNC at L2, 16 (24.2%) of these children required transfer 
to L3 for CPAP or invasive ventilation. The median duration of HFNC was 46.3 h 
(IQR 19.5–93.5) overall, and was 12 h (IQR 4-28) and 58.5 h (IQR 39.5–106) for 
those who failed or were successfully managed on HFNC, respectively. No HFNC-
related serious adverse events were recorded at L2. 
Conclusion: HFNC is a safe, effective, feasible option for non-invasive ventilation of 
children with respiratory illnesses in a resource-limited L2 setting. A greater 
proportion of children admitted with lower respiratory tract infections required 
support in the HFNC-availability group, but the intervention reduced the bed-
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pressure on L3. Improved identification of HFNC failures and better adherence to 
the protocol is needed at L2.  
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4. CHAPTER ONE: BACKGROUND AND LITERATURE REVIEW 
Background 
Acute severe lower respiratory tract infections remain a major cause of mortality and 
morbidity globally (13% mortality)[1,2] and in South Africa.[1] Pneumonia was shown to 
be the leading cause of death in a recent review of mortality among children under 5 
years old in the Metro West geographical service area of the Western Cape 
Province; it accounted for 25% of all deaths.[3] Early and appropriate treatment of 
pneumonia can reduce morbidity and mortality.[4] Comprehensive guidelines have 
been developed, including recommendations contained in the Integrated 
management of childhood illness (IMCI) strategy and South African Thoracic Society 
(SATS) guidelines.[5] Appropriate and rational antibiotic use, supportive care and 
standard low-flow oxygen delivery (nasal prongs or face mask) form part of these 
guidelines.[5,6] However, in most resource-limited countries, mortality from severe 
pneumonia (related to hypoxia and respiratory failure) remains high despite 
implementation of guidelines.[6] Additional respiratory support, central to the care of 
critically ill children, is often unavailable or perceived as not being feasible or safe in 
resource-limited settings.[6,7] 
The use of non-invasive ventilation (NIV), including nasal continuous positive airway 
pressure (CPAP) and high-flow nasal cannula oxygen (HFNC) within and outside 
the paediatric ICU, is growing.[8] The use of simple, self-made CPAP devices has 
been shown to decrease mortality (compared with the use of standard low-flow 
oxygen systems) in children with severe hypoxic pneumonia in a  trial conducted in 
Bangladesh,[9] and researchers in Ghana showed that nurses can successfully and 
safely apply CPAP after receiving appropriate training.[10] Initially, HFNC was only 
used as an alternative to nasal CPAP to provide respiratory support to premature 
infants.[11] Now it is increasingly being utilized in infants and children with a variety of 
underlying reasons for respiratory distress.[12] Evidence from observational studies, 
mostly, indicates that HFNC may provide an increased level of respiratory support 
relatively safely, even outside the intensive care unit (ICU). Most studies to date 
have assessed HFNC use in children with bronchiolitis and have been conducted in 
developed countries.[12] Despite the increased use of HFNC in infants and children, 
there is a paucity of literature to support its use,[12] and no published data exist from 
South Africa or from sub-Saharan Africa. 
 
 
10
10	
	
Objectives 
The objectives of the literature review were: 
• To describe the impact of acute lower respiratory tract infection on paediatric 
morbidity and mortality in the research setting, in South Africa and globally. 
• To review the mechanism of action of HFNC, including concerns regarding 
the provision of positive distending pressure. 
• To review the experience and outcomes of HFNC use in infants and children. 
• To review data on the complications related to HFNC, possible indicators of 
HFNC failure, and costs. 
 
Literature search strategy and search results 
PubMed and replicated searches (as allowed by the search format for HFNC 
studies) in Scopus, Web of Science, Cochrane and Africa wide via EBSCO were 
searched from inception until February 2017 using the following keywords: 
• Children AND infants AND acute lower respiratory tract infection AND 
incidence AND developing countries 
• Children AND acute lower respiratory tract infection AND hypoxia AND 
developing countries 
• Under five child deaths AND western cape 
• Children OR infants AND high flow OR high-flow nasal (cannula OR prong) 
 
The searches were performed in 2017. The search was limited to children aged 0–
18 years, regardless of study design. Preference was given to articles from the 
developing world. Related links and references in the selected articles were 
reviewed. Additional articles and guidelines were included which were 
recommended by either the supervisor or experts in the field. 
The search strategy identified 107 articles: additional studies were included from 
reference list of these articles and from recommendations. A total of 114 full text 
articles were reviewed, and 48 articles were eventually referenced. The majority of 
the articles were from the latter part of the last decade, but 8 articles prior to 2007 
were also included. 
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4.1. HFNC mechanism of action 
Non-invasive ventilation, including nasal CPAP and recently HFNC, involves 
provision of ventilatory support without using an invasive artificial airway. CPAP is 
widely used for children with moderate or severe respiratory distress in ICUs in 
developed countries.[9] 
HFNC provides heated (37°C), humidified (99% relative humidity), unblended or 
blended oxygen and air at flow rates of >1 L/min via nasal cannula.[14,15] Standard 
low-flow nasal cannulae provide dry, mostly cold, unblended oxygen at a flow rate of 
≤1 L/min. Table 1 compares HFNC and nasal CPAP, both of which can provide 
unblended or blended oxygen and air that is heated and humidified.  
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Table 1. Main differences between HFNC and nasal CPAP 
 HFNC Nasal CPAP 
Delivery mechanism Nasal cannula Nasal prongs/mask 
Flow rate >1 L/min (weight dependent) Range: 8 
L/min (neonates) to 50 L/min (adults) 
Variable 
Positive distending 
pressure 
Variable and unregulated Variable and 
regulated 
HFNC, high-flow nasal cannula; CPAP, continuous positive airway pressure. 
 
HFNC likely works via the heating and humidification of inspired air, carbon dioxide 
wash-out of the nasopharyngeal space, reduction in upper airway resistance, and 
the provision of positive distending pressure. [14,16-19] Most physiological studies on 
how HFNC works are either observational studies performed in preterm neonates or 
laboratory-based simulation mode studies. Recently, 4 prospective 
observational/cohort studies were performed in infants and children.[25-28] The 
current paucity of data regarding the unregulated variable positive distending 
pressure provided by HFNC  has raised clinical safety concerns.[12] Many modern 
HFNC devices now have pressure-limiting valves, but more robust physiologic 
studies are needed.[12] 
 
4.1.1 Heating and humidification 
Nasal mucosal drying, injury, infection, impaired clearance of secretions, 
bronchospasm, and patient discomfort can be overcome by heating and humidifying 
inspired air. This also allows for more comfortable provision of higher flow rates.[14] 
Warming and humidifying gases in the nasal passages requires energy.[16] Providing 
warm, humidified gases decreases the patient’s metabolic demand and can be 
beneficial in patients with impaired pulmonary function. Hollerman-Duray et al. 
showed better growth in neonates treated with HFNC rather than nasal CPAP, 
ascribed to a reduction in energy needs in the HFNC group.[17]  
 
4.1.2 Nasopharyngeal carbon dioxide wash-out 
The presence of end-expiratory gas in the nasopharyngeal dead space at the 
beginning of inspiration reduces the efficacy of gas exchange. HFNC has a similar 
13
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action to tracheal gas insufflation which washes out the nasopharyngeal dead 
space. Tracheal gas insufflation has been shown to reduce inspiratory ventilation 
pressures, volume requirements and PaCO2.[16]   
 
4.1.3 Reduction in upper airway resistance 
The large surface area of the nasopharynx increases inspiratory resistance. It is 
proposed that HFNC may improve inspiratory resistance by stenting the upper 
airway, similarly to CPAP.[16,18] HFNC also provides nasopharyngeal gas flow similar 
to or greater than the patient’s own inspiratory flow, improving tidal volume and 
reducing work of breathing.[16]  
 
4.1.4 The provision of positive end expiratory pressure (PEEP) 
HFNC can produce PEEP[19] but the definitive pressures generated have not been 
consistently measured and show significant variation (in the limited studies 
published to date). Measuring nasopharyngeal, oesophageal, and tracheal 
pressures are ways of estimating the PEEP provided.[21] Initial HFNC physiology 
studies were done in preterm neonates in a neonatal ICU setting. Spence et al. 
showed an average PEEP of 4.8 cm H2O at flows of 5 L/min in premature 
neonates,[19] while Sreenan et al. showed a relationship between the PEEP 
generated and infant weight.[22] Interestingly, Lampland et al. showed that end-
expiratory oesophageal pressure was much lower than 6 cm H2O even at flows of 6 
L/min with a closed mouth,[23] and Saslow et al. showed no noteworthy increase in 
PEEP at flows of 3, 4, and 5 L/min in preterm neonates.[24]  
Table 2 shows the HFNC physiological studies performed in infants and children 
outside the neonatal period. Important  limitations of the studies are the small 
numbers of subjects,[25-29] technical problems (placement of pressure catheters),[29] 
and changes in PEEP possibly related to air leaks and mouth closure.[25] 
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Table 2. HFNC physiological studies performed in infants and children outside the 
neonatal period 
Study  
 
Setting and 
participants 
Study Type Outcomes Findings 
McGinley 
et al. 
2009[26] 
n=12 
Study ward 
Mean age 10.1 
years 
All participants 
had obstructive 
sleep apnoea 
and were obese, 
receiving 
HFNC 20 L/min 
Prospective 
cohort study 
Sleep architecture 
Sleep disordered 
breathing 
Arousal indexes 
Inspiratory flow 
limitations 
Respiratory rate (RR) 
Inspiratory duty cycle 
Decreased arousals 
Decreased obstructive 
episodes 
Reduced amount of 
inspiratory flow 
limitations leading to 
reduced RR and insp. 
duty cycle 
Arora et 
al. 
2012[25] 
n=25 
Emergency 
department 
Mean age: 78.1 
days/5.3kg 
Prospective 
observationa
l study 
Nasopharyngeal 
pressure (NP) 
Vital signs 
Oxygen saturation 
Bronchiolitis severity 
score 
Linear increase in NP 
pressure with flows up 
to 6 L/min. Significant 
differences between 
pressures in open and 
closed mouth states. 
PEEP was not 
affected by weight or 
sex 
A clinical severity 
score improved in 
subjects 
Milesi et 
al. 
2013[27] 
n=21 
PICU 
Infants < 6 
months old with 
acute RSV 
bronchiolitis on 
HFNC 
Prospective 
observationa
l study 
 
 
Pharyngeal pressure 
(PP) and 
oesophageal 
pressure (OP) 
Flow >2 L/kg/min 
generated a mean 
PEEP >4 cm H2O 
(measured at flows of 
1,4,6, and 7 L/min 
Convincing reduction 
in respiratory rate from 
start to max flow rate. 
Rubin et 
al. 
2013[28] 
n=25 
PICU 
Infants/children 
<18 years on 
HFNC 
Very 
heterogeneous 
Prospective 
cohort study 
OP 
Changes in pleural 
pressure, RR. Rate 
product (objective 
measure of effort of 
breathing) 
Convincing reduction 
(25%) in effort of 
breathing with 
increase flow from 2 
L/min to 8 L/min  
15
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group with co-
morbidities 
Mean age 6.5 
months. 
Mean weight 6.4 
kg 
Hough et 
al. 
2014[29] 
n=11 
PICU 
Infants with 
bronchiolitis on 
HFNC 
Mean age 3.17 ± 
2.06 months. 
Mean weight 
4.76 ± 1.39 kg. 
Prospective 
observationa
l study 
 
OP 
Regional tidal volume 
(RTV) 
End-expiratory lung 
volumes (EELV) 
FiO2 
RR and oxygen 
saturation 
Measured and 
compared 2 L/min vs 8 
L/min: Increased end-
expiratory pressure, 
not end-inspiratory 
pressure with flow 1.7 
L/kg/min (by definition 
not 
continuous/CPAP)-
may need higher flows 
to achieve. 
Increase EELV 
anterior lung, not 
posterior lung on 
HFNC 
No statistical 
significant difference 
in RTV 
Decrease in RR, nil 
difference in the other 
physiological 
parameters 
 
Pham et 
al.[30] 
2014 
n=28 
PICU 14 infants 
with bronchiolitis 
and 14 cardiac 
patients 
Prospective 
study 
Diaphragmatic 
electrical activity and 
oesophageal 
pressure off and then 
on HFNC at 2 
L/kg/min 
Signiﬁcant reduction in 
oesophageal 
pressures and 
diaphragmatic activity 
as an estimate of the 
work of breathing. 
Decrease in 
respiratory rate 
HFNC, high-flow nasal cannula; PICU, paediatric intensive care unit. 
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In summary, a few limited  physiological HFNC studies done outside of the neonatal 
period do show increased PEEP with increased flow rates,[25, 27] possibly to a 
maximum of 6–8 L/min, likely influenced by mouth closure [25] and a reduction in 
respiratory rate and work of breathing in the small number of study subjects.[25, 27-29] 
 
4.2. Experience in HFNC use in infants and children and outcomes 
Initially HFNC was only used as an alternative respiratory support to nasal CPAP for 
premature infants,[11] but is now increasingly used in infants and children with a 
variety of causes for their respiratory distress[12] and in various settings. Most studies 
were performed in the PICU setting in developed countries; newer studies have 
shown promise for the use of HFNC in emergency departments,[46] during inter-
hospital transport of ill children,[43] and in paediatric wards.[39] A recent guideline on 
high dependency care for children in the United Kingdom suggests that HFNC is an 
intervention that should be available to all children admitted to all inpatient 
facilities.[31] Despite the increased use of HFNC, there is a paucity of literature to 
support its use in children[12] and no published data are available from South Africa 
or from sub-Saharan Africa. 
 
4.3.1 HFNC use in developing countries:  
Review of the trial by Chisti et al.[9] in Bangladesh 
The study by Chisti et al.[9] stands out as the only published data on HFNC use in 
children with severe pneumonia and hypoxia in a developing country. This open, 
randomised, single-centre clinical trial, comparing outcomes of children with severe 
pneumonia managed with bubble CPAP, HFNC (flow range: 2–12 L/min), or low-
flow oxygen therapy (LFNC) was conducted at Dhaka hospital, Bangladesh. This is 
a large tertiary hospital (with mechanical ventilation available on site) closely 
connected to a research centre. Unfortunately, the trial was stopped at the second 
interim analysis, prior to reaching projected sample size (325 per treatment group), 
due to the marked difference in the number of deaths occurring between the 
treatment groups. 
In total, 225 children aged <5 years with severe pneumonia (WHO criteria) and 
hypoxia (SpO2 <90%) were randomized to 3 treatment groups. Exclusion criteria 
included preterm neonates; children with congenital cardiac disease, asthma, or 
17
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upper airway obstruction; and children meeting “treatment failure “criteria at 
presentation. The high incidence of co-morbidities (similar in each treatment 
group)—especially severe malnutrition (22%) and severe sepsis (8%)—makes the 
study particularly relevant to other developing countries where children present with 
similar co-morbidities. No commercial devices were used in the study. Both the 
bubble CPAP and HFNC devices were “self-made” with low cost and used available 
tubing and materials; hence, the interventions are feasible in resource-limited 
settings. 
The primary outcomes included treatment failure (defined as 2 or more of following 
characteristics: severe hypoxia, signs of severe clinical distress, or respiratory 
acidosis on blood gas analysis) after at least 30 minutes of the intervention, 
intubation/mechanical ventilation (within the first 30 days), death (at any time during 
hospitalization), and leaving the hospital against medical advice. Secondary 
outcomes included length of hospital stay, nosocomial infections, isolation of 
Mycobacterium tuberculosis or another bacterial pathogen, and multi-organ failure in 
the first 7 days of respiratory support. Further analysis also assessed the time to 
resolution of hypoxia, normalization of the respiratory rate, and resolution of the 
signs of respiratory distress. 
The study showed that mortality was significantly lower among children 
receiving bubble CPAP than among those receiving either LFNC or HFNC 
oxygen therapy, even after adjusting for all identifiable risk factors. The 
proportion of children that died was similar in the LFNC and HFNC groups. 
However, there was no significant difference between bubble CPAP and HFNC in 
terms of treatment failure. Although not statistically significant, children receiving 
HFNC had slightly shorter times to resolution of hypoxia and normalization of 
respiratory rates than those receiving LFNC. The relevance of this study is 
unquestionable for further research in advanced respiratory support for ill children in 
resource-limited settings. 
The Children’s Oxygen Administration Strategies Trail (COAST)[49] is a multicentre 
(5 hospitals) RCT, currently enrolling (start February 2017-over 30 month period) in 
East Africa (Kenya).The trail will simultaneously evaluate 2 related interventions in 
children with pneumonia, namely liberal oxygen compared with so called permissive 
hypoxia (Sp02>80%) and high flow oxygen vs low flow delivery (current routine 
care).Primary outcome will be mortality at 48 hours. Outcomes and results will 
18
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contribute new knowledge not only to host response to oxygen strategies but 
outcomes ito of high flow vs low flow oxygen delivery will be very interesting.   
 
4.3.2 HFNC use in developed countries 
HFNC use in bronchiolitis 
Viral bronchiolitis contributes significantly to infant mortality and morbidity in both the 
developed[32] and developing world.[1] Besides respiratory support and adequate 
nutrition effective treatment for bronchiolitis is limited.[33] The efficacy of breathing is 
reduced in infants with bronchiolitis who are uncomfortable and distressed.[20] The 
use of HFNC in children with bronchiolitis, as an alternative to CPAP, is an attractive 
option as it is well tolerated.[25, 27] Data related to HFNC use in bronchiolitis comes 
mostly from small observational studies; a recent review by Sinha et al.[20]concludes 
that more high quality randomized controlled trials (RCTs) using standardized 
methodology for bronchiolitis, directly comparing CPAP, HFNC, and standard low-
flow oxygen delivery, are required.[20]  
Randomized clinical trials  
Hilliard et al.[34] compared HFNC to head box oxygen delivery in 19 infants with 
moderate to severe bronchiolitis (tertiary hospital setting). The primary outcome was 
SaO2 at 8 h. The higher SaO2 measurement observed in the HFNC group was not 
significant and likely reflected the higher inspired oxygen concentrations in the group 
at that time point. There was no difference in the time required to wean to nasal 
cannula oxygen or air, time to starting feeds, or in the duration of hospital stay. 
Bueno Campana et al. [35] compared HFNC with nebulized hypertonic saline in 74 
infants with moderate bronchiolitis in a regional hospital setting. The researchers did 
not demonstrate any difference in respiratory distress, as measured by the 
Respiratory Assessment Change Score, between the 2 groups at any time point 
during the 36 h post-randomization. Additional outcomes were a comfort score, 
length of stay, and rates of PICU admission. No difference was shown in these 
outcomes between the 2 groups. However, a recent study by Maquire et al. 
concludes that there is currently no robust evidence that hypertonic saline is an 
effective intervention in bronchiolitis. [33] 
Published data from 2 new studies, Kepreotes et al.[36] (setting: paediatric 
emergency centres) trial and the PARIS (Paediatric Acute Respiratory Intervention 
19
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Study) trial,[37] are eagerly awaited. Both compared standard LFNC with HFNC 
therapy in infants with bronchiolitis. The PARIS study is a multi-centre RCT 
comparing standard low-flow nasal cannula oxygen with HFNC in infants aged <12 
months with hypoxic bronchiolitis. Exclusion criteria are infants with an urgent need 
for respiratory support (including needing non-invasive or invasive ventilation, a low 
level of consciousness, and apnoea), cyanotic heart disease, basilar skull fracture, 
upper airway obstruction, craniofacial malformations, and infants who are already on 
home oxygen therapy. Infants will be recruited from general wards and emergency 
departments. The primary outcome is treatment failure (as determined by definitive 
criteria). The secondary outcomes include the number of infants requiring transfer to 
higher level of care (including admission to an on-site paediatric intensive care or 
transfer to a tertiary hospital) length of hospital stay (including ICU length of stay); 
intubation rates; associated healthcare costs for the respective therapy; length of 
oxygen therapy; and adverse events. Both developed and developing countries may 
find these study results very relevant to appropriate, safe, and cost-effective 
respiratory support for young infants with bronchiolitis.  
 
Observational studies 
The key limitation of most of the observational studies is the small number of study 
subjects. [25, 27, 30, 38-40] Moreover, all were single centre studies and the groups were 
poorly comparable. [38, 40] 
Retrospective studies 
PICU setting: McKiernan et al.[41] reviewed 115 infants (mostly <6 months of age) 
with bronchiolitis receiving HFNC (maximum flow rate: 8 L/min).They showed a 
statistically significant decrease in respiratory rate, need for intubation, and length of 
stay. Metge et al. [38] compared HFNC and CPAP in 34 infants with bronchiolitis 
caused by respiratory syncytial virus (RSV); a significant reduction in respiratory 
rate, heart rate, PaCO2, and FiO2 was demonstrated within groups, but not between 
groups. 
 
Prospective studies: 
PICU setting: The study by Arora et al.[25] showed a statistically significant reduction 
in severity scored in 25 infants with bronchiolitis receiving HFNC therapy in PICU. 
20
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Although predominantly a physiological study in a PICU, Milesi et al.[27] also showed 
a convincing reduction in respiratory rate from start to maximum flow rate in 21 
infants with bronchiolitis due to RSV. Pham et al.,[30] in a small physiological, study 
showed a reduction in effort of breathing and respiratory rate in 14 infants with 
bronchiolitis. 
General paediatric ward: Bressan et al.[39] prospectively reviewed 27 very young 
infants (mostly aged <2 months) with moderate-to-severe bronchiolitis receiving 
HFNC in a general paediatric ward. Primary outcomes were SpO2, end-tidal carbon 
dioxide (ETCO2), and respiratory rate (RR) measured for a baseline period of 1 h 
before and at specific time intervals within 48 h after initiating HFNC. They showed a 
statistically significant median SpO2 increase changing from standard oxygen to 
HFNC. The median ETCO2 and RR decreased rapidly and significantly in the first 3 
h of HFNC therapy and remained stable thereafter. There were no reported 
complications related to HFNC use and none of the patients required PICU 
admission. 
Milani et al.[40] recently prospectively compared 36 infants aged <12 months with 
bronchiolitis who were treated with either LFNC or HFNC oxygen therapy in a 
general paediatric ward. Their exclusion criteria were premature infants, recurrent or 
chronic lung disease, heart disease, neurological problems, and those requiring 
admission to PICU. Improvements in RR, respiratory effort (measured at 30 min and 
1, 24, and 72 h) and ability to feed occurred significantly more quickly in the HFNC 
group; this may explain the shorter length of hospital stay in the HFNC group. 
Limitations are summarized above.  
 
HFNC use in respiratory distress due to other causes in children 
Only a few studies on HFNC use in children with respiratory conditions other than 
bronchiolitis were identified. As reviewed, Chisti et al.[9] used HFNC in children with 
severe pneumonia. In a recent single-centre, randomised trial comparing HFNC with 
low-ﬂow oxygen therapy after extubation in postoperative paediatric cardiac patients 
(aged <18 months), Testa et al.[42] showed higher partial pressure of oxygen/FiO2 in 
the HFNC therapy group at each time point during the 48-hour study period. No 
difference in PaCO2 value was shown at any time-point. In the low-ﬂow oxygen 
group, 15% of patients needed non-invasive respiratory support; none in the HFNC 
therapy group required this. 
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A single-centre retrospective review showed a reduction in the need to intubate in 
an emergency department when HFNC is introduced early in children with 
pneumonia, asthma, bronchiolitis, and croup.[43] McGinley et al.[26] showed improved 
outcomes in children with obstructive sleep apnoea. Successful use of HFCN has 
been reported in case series/reports in patients with viral-induced wheeze and post-
intubation stridor.[44, 45] 
Sclhapbach et al.[46] analysed their experience of HFNC use during inter-hospital 
transport of critically ill children (aged <24 months). They assessed 793 children 
over an 8-year period. A comparison was made between the period prior (4 years) 
and during (4 years) the availability of HFNC for inter-hospital transport. During the 
period of HFNC availability, a third of children received HFNC therapy en route, and 
there was a signiﬁcant decrease in the number of children requiring retrieval on 
invasive ventilation (14%). Retrieval rates on non-invasive ventilation declined from 
7% to 2%. There was no statistically signiﬁcant change in the number of retrieved 
children requiring intubation for respiratory reasons during the ﬁrst 24 h after PICU 
admission. 
 
4.4. HFNC Complications 
 
4.4.1 Air leaks 
In a case series, Hedge et al.[47] described 2 cases of pneumothorax and 1 case of 
pneumomediastinum occurring in children receiving HFNC. 
 
4.4.2 Gastric distension 
Abdominal distension has been reported in 2 patient reports.[42] 
 
4.4.3 Infection 
In 2005, an outbreak of infection with Ralstonia spp. occurred in children in the USA; 
it was linked to the use of the Vapotherm 2000i HFNC therapy system. The device 
was recalled and changes were made. After reintroduction, no further problems 
were reported. [48] 
 
Summary 
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Acute severe lower respiratory tract infections remain a major cause of mortality and 
morbidity in South Africa[1] and globally (13%).[1, 2] Interest in, and use of, non-
invasive ventilation for respiratory support, including nasal CPAP and HFNC within 
and outside the paediatric ICU, is growing.[7, 8] The literature search shows that there 
is  paucity of robust literature  and evidence to support the use of HFNC in children 
outside the PICU setting and in conditions other than bronchiolitis.[12] More clarity is 
needed on the mechanism by which HFNC provides PEEP, which appears variable. 
A brave, contextually relevant study from Bangladesh showed no difference in 
“treatment failure” outcomes (defined as 2 or more of following characteristics: 
severe hypoxia, signs of severe clinical distress, or respiratory acidosis on blood gas 
analysis) in severe pneumonia comparing bubble CPAP with HFNC, but mortality 
rates were higher in this setting in the LFNC and HFNC groups, indicating potential 
risk for harm associated with these modalities. HFNC had no impact on mortality 
compared with LFNC therapy.[9] Awaited data from 2 new RCTs comparing HFNC 
with standard LFNC will be important. Deductions from mostly observational studies 
show that HFNC reduces the RR and effort of breathing in infants with bronchiolitis, 
appears safe (with very few reported complications), and is well tolerated. 
Commercial HFNC devices, deemed safer, are expensive. Guaranteeing that an 
appropriate, cost-effective form of respiratory support is delivered in a safe 
environment and that children requiring escalation of respiratory support are 
identified early are key to utilizing a resource/intervention effectively, especially in a 
resource-limited environment. Therefore, more research is needed to ensure the 
safe use and implementation of HFNC therapy. 
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Abstract 
Background. High-flow nasal cannula oxygen (HFNC) is a non-invasive alternative 
to nasal continuous positive pressure oxygen (CPAP) therapy for infants and 
children requiring respiratory support. There is a paucity of literature to support its 
use in children, with no published data from sub-Saharan Africa. 
Objective. To describe the outcomes and adverse events of HFNC in the first year 
of its use in a level two (L2) general paediatric ward, compared with outcomes of an 
historical cohort when this intervention was unavailable. 
Methods. This retrospective descriptive study included children aged <13 years 
who received HFNC in the first 12 months after its introduction (HFNC-availability 
group; n=66). Demographic data, clinical characteristics, and outcomes (death, 
treatment failure, length of HFNC, and HFNC-related adverse events) were 
assessed. A comparative description of children that required transfer to level 3 (L3) 
for respiratory support (more than available standard low-flow oxygen) in the 12-
month period prior to HFNC availability (pre-HFNC group; n=54) was performed and 
outcomes were compared using standard descriptive and comparative statistics. 
Results.	The median age of the cohort was 5 months (interquartile range [IQR] 1.9–
14.6). Sixteen children (13.3%) were malnourished, 10 (8%) were HIV infected, and 
30 (25%) were ex-premature infants. The most common diagnoses were 
pneumonia, bronchiolitis, and asthma. Asthma, anaemia, and cardiac abnormalities 
were the most prevalent underlying co-morbidities. Two children died in each group. 
All 54 children in the pre-HFNC group were transferred to L3; 38 (70.4%) needed 
CPAP or invasive ventilation. In the HFNC-availability period, 85 children were 
assessed as needing more than standard low-flow oxygen therapy: 19 were 
immediately transferred to L3 where 17 (89.4%) received CPAP or invasive 
ventilation; 66 received HFNC at L2, 16 (24.2%) of these children required transfer 
to L3 for CPAP or invasive ventilation.  
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The median duration of HFNC was 46.3 h (IQR 19.5–93.5) overall, and was 12 h 
(IQR 4-28) and 58.5 h (IQR 39.5–106) for those who failed or were successfully 
managed on HFNC, respectively. No HFNC-related serious adverse events were 
recorded at L2. 
Conclusion. HFNC is a safe, effective, feasible option for non-invasive ventilation of 
children with respiratory illnesses in a resource-limited L2 setting. A greater 
proportion of children admitted with lower respiratory tract infections required 
support in the HFNC-availability group, but the intervention reduced the bed-
pressure on L3. Improved identification of HFNC failures and better adherence to 
the protocol is needed at L2.  
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INTRODUCTION 
Acute severe lower respiratory tract infections continue to be a major cause of 
mortality and morbidity globally (13%)[1,2] and in South Africa.[1] Reid et al. showed 
that pneumonia (25%) was the main cause of death in children under 5 years of age 
in the Metro West health district of the Western Cape Province in South Africa.[3] In 
many middle-to-low income countries with resource limitations, the number of child 
deaths resulting from severe pneumonia (related to hypoxaemia and respiratory 
failure) remains high, despite implementation of international and local guidelines.[4] 
Additional respiratory support, important in the care of critically ill children, is often 
unavailable or is perceived as being neither feasible nor safe in resource-limited 
settings.[4,5] The use of non-invasive ventilation for respiratory support, including 
nasal continuous positive airway pressure (CPAP) and high flow nasal cannula 
(HFNC) within and outside the paediatric intensive care unit (PICU), is increasing.[5,6] 
There is limited evidence to support the use of HFNC in children outside the PICU 
setting and in conditions other than bronchiolitis.[7]  
The probable mechanisms of action of HFNC includes heating and humidification of 
inspired air, nasopharyngeal carbon dioxide wash-out, reduction in upper airway 
resistance, and the provision of positive distending pressure.[8, 9-12] The current 
paucity of data regarding the variable positive distending pressure provided by 
HFNC remains controversial and has raised clinical safety concerns[7]; many modern 
HFNC devices now have pressure-limiting valves. However, more robust 
physiological studies are needed. [7]  
A pioneering, contextually relevant study from Bangladesh showed that 
outcomes in terms of "treatment failure" (defined as 2 or more of following 
characteristics: severe hypoxia, signs of severe clinical distress, or respiratory 
acidosis on blood gas analysis) were no worse in patients with severe pneumonia 
who received HFNC compared with bubble CPAP, but mortality rates were higher 
in the LFNC and HFNC groups, indicating potential risk for harm associated with 
these modalities [13].Results from The Children’s Oxygen Administration Strategies 
Trail (COAST)[20], a multicentre (5 hospitals) RCT, currently enrolling (start February 
2017-over 30 month period) in East Africa (Kenya) will be very interesting. The trail 
will simultaneously evaluate 2 related interventions in children with pneumonia, 
namely liberal oxygen compared with so called permissive hypoxia (Sp02>80%) and 
high flow oxygen vs low flow delivery (current routine care).Primary outcome will be 
mortality at 48 hours. Outcomes and results will contribute new knowledge not only 
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to host response to oxygen strategies but also outcomes ito of high flow vs low flow 
oxygen delivery will be very interesting. Various observational studies have shown 
that HFNC reduces respiratory rates and the effort of breathing in infants with 
bronchiolitis, has very few reported complications, and is well tolerated.[7] Awaited 
data from two new upcoming randomized trials comparing HFNC with standard 
LFNC in bronchiolitis will be important.   
Commercial HFNC devices and circuits are expensive. Guaranteeing that a clinically 
effective and cost-effective form of respiratory support is delivered in a safe 
environment and that children requiring escalation of respiratory support are 
identified early, are crucial to the appropriate utilization of a new intervention, 
especially in a resource-limited environment. Consequently, more research is 
needed to document efficacy and safety in various clinical scenarios. 
The donation in 2015 of two commercial HFNC devices to the general paediatric 
ward of New Somerset Hospital (NSH), a level 2 (L2) hospital in the Metro West 
sub-district of Cape Town, afforded the pragmatic opportunity to review this new 
intervention. Prior to the availability of on-site HFNC, all children that might require 
additional respiratory support (HFNC, CPAP, or intermittent positive pressure 
ventilation [IPPV]) were transferred by ambulance to the level 3 (L3) children’s 
hospital that has dedicated high care and PICU facilities. The objectives of this study 
were to document the first year of experience using HFNC by describing the 
demographic and clinical characteristics of children who qualified (by protocol) and 
were initiated on HFNC oxygen therapy on site, and to evaluate their response to 
the intervention. 
 
METHODS 
Study design and participants  
This was a retrospective descriptive study of hospitalized children < 13 years of age 
managed with HFNC oxygen therapy in the general paediatric ward of NSH during 
the first 12 months of its availability (1 August 2015 to 31 July 2016). A comparison 
was made with children < 13 years of age who required transfer for additional 
respiratory support for respiratory distress in the 12 months prior to the availability of 
HFNC oxygen therapy at the same institution (1 August 2014 to 31 July 2015). 
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The children commenced on HFNC oxygen according to departmental guidelines 
were identified from the ethics-approved NSH High Flow Nasal Cannula Registry 
(R051/2015). The children transferred to tertiary care for respiratory support in the 
preceding year were identified from existing routine morbidity and mortality records 
of the Department of Paediatrics at NSH.	The Research Ethics Committee of the 
University of Cape Town granted ethical approval for this study (approval no. 
R051/2015) and waived the need for informed consent due to the retrospective 
nature of the study and the use of routine clinical data. 
 
Setting 
NSH is a 330-bed secondary level (L2) hospital, i.e. there are specialists on site, 
but no sub-specialty service is offered. The paediatric population served 
comprises approximately 100 000 children, mostly from middle and lower 
socioeconomic backgrounds (many from informal housing areas). There is no PICU 
on site and children requiring advanced respiratory support need to be transported 
to a tertiary level (L3) hospital (where sub-speciality services and PICU facilities are 
available) that is approximately 30 minutes’ away by road ambulance transport. 
Staffing (both nurses and doctor numbers) were the same in the 2 study periods. All 
children with respiratory distress requiring oxygen therapy would be monitored 
closely in the paediatric ward. Supportive care and feeding by nasogastric tube 
when children are moderately or severely distressed is standard care in the ward.   
 
HFNC system and protocol 
The HFNC equipment used at NSH is a Fisher and Paykel® system (Fisher & 
Paykel Healthcare Limited Auckland New Zealand) with a humidifier, and age and 
weight appropriate Fisher and Paykel® nasal cannula. The NSH HFNC oxygen 
guideline was adapted for local use from the Royal Children’s Hospital Melbourne 
guideline.[14]  Starting flow rates were based on the weight of the child: < 10 kg: 2 
L/kg/min and >10 kg: 2 L/kg/min for the first 10 kg plus 0.5 L/kg/min for each kg 
above 10 kg with max flow 50 L/min. The decision to commence HFNC always 
involved a senior paediatrician. Both nurses and doctors working in the ward 
received basic training in the use of the device and the children receiving HFNC had 
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hourly observations performed, including pulse oximetry, and measurement of the 
respiratory rate (RR) and heart rate (HR). 
The guideline’s suggested indications for HFNC include use in children with 
moderate-to-severe respiratory distress with hypoxaemia (SpO2 < 90%) despite 
standard low-flow oxygen (provided by nasal prong or face mask) due to common 
childhood respiratory illnesses (community-acquired pneumonia [CAP], bronchiolitis, 
and asthma exacerbations). Absolute contra-indications for HFNC use include the 
need for immediate invasive respiratory support and infants or children with non-
patent nasal passages.  
Children receiving HFNC were monitored and reviewed both 30 min and 
approximately 2 h after being initiated on HFNC to determine whether transfer 
and/or additional support was required. No improvement in the RR and HR (> 20% 
reduction not achieved), the inability to wean the FiO2 to < 40%, or worsening 
respiratory distress indicated treatment failure and the need to transfer the child for 
advanced respiratory support.  
 
Data collection and definitions 
The medical folders of identified patients were drawn from the medical records 
department, reviewed, and relevant data entered into an electronic data capture 
sheet (Microsoft Access®). Any results and details not recorded in the medical 
folder were searched for through the electronic National Health Laboratory Service 
and Clinicom platforms. 
The data collected comprised patient demographic information (sex, age), 
diagnosis, underlying co-morbidity, gestational age at birth, birth weight, and 
nutritional and human immunodeficiency virus (HIV) status. HIV status was 
classified as uninfected, exposed but uninfected, and infected. Due to the small 
number of HIV-infected children, no distinction was made according to whether 
these children were taking combined antiretroviral treatment (cART), were pre-
cART, or had defaulted cART, or according to their immunological or virological 
status. The nutritional status of each child was determined by the weight-for-age z-
score (WAZ score) and the weight-for-height/ length z-score (WHZ). These z-scores 
were calculated using the "zanthro" function of Stata®/IC 13.0 statistical software, 
with the World Health Organization (WHO) 2007 UK term and preterm growth charts 
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used for reference (Birth: British 1990 Growth Reference, reanalysed 2009; 
Postnatal: WHO Child Growth Standards; 4-20 years: British 1990 Growth 
Reference). Hence, prematurity was taken into account in the calculation of the z-
scores. Malnutrition was defined as a WAZ score <-2. The method of delivery of 
standard low-flow oxygen support received by transferred children in the pre-
intervention group was collected.  
The baseline number of monthly admissions was available from routine 
departmental data on total admissions for acute respiratory tract infections in 
children aged < 5 years. Despite not including all ages we thought that this would be 
a reasonable approximation of total number of acute respiratory tract infections 
admissions given that 90% of our total cohort was < 5 years of age, and the older 
group were mostly children with asthma who would not be counted in the baseline 
data. 
 
Data Analysis  
The data analysis was performed using Stata®/IC 13.0 statistical software (Stata-
Corp LP, TX77845, USA). Continuous data were tested for normality using the 
Shapiro-Wilks test, and are presented as the median (interquartile range [IQR]) or 
mean (standard deviation [SD]) for non-normally and normally distributed data, 
respectively. Medians and means were compared between groups using the 
Wilcoxon rank sum or Student’s t-test, respectively. Categorical data are presented 
as the frequency and percentage, with the chi-squared or Fisher’s exact test used 
for comparison between groups, as appropriate. For all tests p-value < 0.05 was 
considered significant. 
 
Outcome measures 
The primary outcomes when comparing the pre-intervention (pre-HFNC) and post 
intervention (HFNC) groups were to document the success of the intervention, 
defined as no need for escalation of respiratory support; the failure of the 
intervention, defined as needing further non-invasive (CPAP) or invasive (IPPV) 
respiratory support within 48 h of transfer; and death during admission. Secondary 
outcomes in the HFNC group were the length of time receiving HFNC and severe 
adverse events associated with HFNC use in a general ward. 
36
37	
	
	
 
RESULTS 
In the first 12 months of on-site availability of HFNC in the general paediatric ward (1 
August 2015 to 31 July 2016), 66 infants and children received HFNC oxygen 
therapy. In the pre-HFNC-availability period (1 August 2014 to 31 July 2015) during 
which only standard low-flow oxygen respiratory support (nasal prong oxygen or 
face mask oxygen) was available, 54 children required transfer to a L3 hospital for 
further respiratory support. 
 
Demographic and clinical characteristics 
The median age of the whole study cohort was 5 months (IQR 1.9–14.6), with a 
slight male preponderance (Table 1). Of the study population for whom nutritional 
data was available (106/120), 15.1% (16/106) were moderately or severely 
malnourished with more children malnourished in the pre-HFNC group (31.1%, 
14/45) than in the HFNC group (3.3%, 3/61). A significantly greater proportion of 
children were HIV-infected or HIV-exposed in the pre-HFNC group than in the HFNC 
group. Among children with underlying comorbid conditions (n = 58), asthma and 
anaemia were the most prevalent, being present in 24.1% (14/58) and 17.2% 
(10/58) of these children, respectively, and 12.1% (7/58) had an underlying 
congenital cardiac abnormality. The most common diagnosis was pneumonia (n = 
84 [70.0%]), followed by bronchiolitis, then asthma. Of those < 5 years of age, the 
majority of children (n = 82 [76.6%]) had pneumonia, whereas in the older age group 
(> 5 years) the majority (n = 11 [84.6%]) had asthma. A quarter of the study 
population comprised ex-premature infants.  
 
Comparison of outcomes between the groups 
Death during admission 
There was no difference between the HFNC availability group and pre-HFNC 
availability groups in terms of the proportion of children who died, with 2 deaths 
(3.7% vs 3.0%, respectively) in each group. The children that died in the HFNC 
group were 4 and 13 months old. Both were HIV unexposed and uninfected, neither 
were malnourished, and both had an initial diagnosis of pneumonia. The 4-month-
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old child had no underlying co-morbidities and was transferred within 12 h of 
commencing HFNC to the L3 hospital for invasive respiratory support where he died 
8 weeks later of intractable respiratory failure secondary to severe 
bronchopneumonia. The 13-month-old child had significant underlying co-
morbidities, with Down’s syndrome, hypothyroidism, gastro-oesophageal reflux 
disease, and evidence of chronic lung disease. He received HFNC oxygen for 9 
days during his stay and was weaned off successfully but unexpectedly died at the 
regional hospital after a 5-week hospital admission. The cause of death was 
aspiration. 
Need for escalation of respiratory support 
Figure 1 shows the study flow. In the pre-HFNC-availability group, 54/835 (6.5%) 
children admitted for acute lower respiratory tract infections (LRTIs) were assessed 
as needing transfer to the L3 hospital for possible additional respiratory support. Of 
the 54 children transferred, 38 (70.4%) required CPAP or IPPV within 48 h of 
transfer, or died, while 16 (29.6%) received HFNC or remained on nasal prong 
oxygen at the L3 hospital. 
In the HFNC availability group, 85/604 (14%) of children admitted for acute LRTIs 
were assessed as needing more than standard low-flow oxygen therapy; 66 (10.9%) 
were initiated on HFNC in the general ward at NSH while 19 (3.1%) were assessed 
as needing more support than HFNC and were transferred directly to L3. Overall, 33 
(5.5%) children admitted for acute lower tract respiratory infections were eventually 
transferred to L3. Of the 19 children assessed as requiring transfer to L3 without 
being offered on-site HFNC oxygen, the majority 17 (89.4%) received CPAP or IPPV 
at the referral facility, while 2 (10.5%) were managed with HFNC or nasal prong 
oxygen. Of the 66 children initiated on HFNC in the general ward, 50 (75.8%) were 
successfully managed and successfully weaned off HFNC and discharged home. 
The other 16 (24.2%) were assessed as not settling on HFNC and were transferred 
to L3 within 48 h of being on HFNC. At L3 they received either CPAP or IPPV, and 1 
died after prolonged ventilation. 
  
The HFNC group 
Length of time receiving HFNC 
The overall median duration on HFNC was 46.3 h (IQR 19.5–93.5 h). Of the 16 
children who failed HFNC at NSH, the median duration on HFNC was 12 h (IQR 4–
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28 h). Among those who were successfully managed on HFNC, the median time on 
HFNC was 58.5 h (IQR 39.5–106 h). Four children required HFNC for longer than 7 
days (range: 9 days [231 hours] and 13 days [322 hours]); one of these patients 
died. 
 
Serious adverse effects in HFNC group 
No pneumothoraces, episodes of gastric or abdominal distention, mucosal injury, or 
infections were documented for any of the children receiving HFNC oxygen therapy 
in the general ward of NSH in the first 12 months of its use.  
Of the infants who failed HFNC at L2 and were transferred to L3, most were boys (n 
= 12, 75%) and the median age of the 16 infants was 6.7 months; 10 (63%) were < 
6 months old. The attending doctor’s interpretation of the children’s x-ray images 
showed that 15 of the infants had hyperinflation and either focal areas of 
opacification or changes consistent with bronchopneumonia. Fifteen had blood 
cultures performed (all results were negative) and 12 (75%) had a nasopharyngeal 
aspirate (NPA) done at L3. Two children’s NPA specimens were negative and 10 
(83%) tested positive for respiratory viruses; 5 were positive for adenovirus, 3 tested 
positive for both adenovirus and respiratory syncytial virus (RSV), one specimen 
was only RSV positive, and one was influenza virus positive. The vital sign 
monitoring data (HR, RR, Fi02, and oxygen saturation) of the 16 children that failed 
HFNC, recorded hourly at L2, were reviewed; no consistent pattern predicting failure 
was observed.  
 
DISCUSSION 
This is the first study from sub-Saharan Africa documenting the safe, effective use of 
HFNC in a general paediatric ward setting. We identified no complications and 
demonstrated an increased capacity of a L2 hospital to manage children who 
require more than standard low-flow oxygen respiratory support, reducing pressure 
on L3 services. Children who were initiated on HFNC oxygen at the L2 hospital and 
subsequently transferred to L3 were also less likely to require CPAP or invasive 
ventilation at L3. 
Pneumonia was the predominant diagnosis in the overall study population reflecting 
current evidence that pneumonia is the leading cause of morbidity and mortality in 
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children in South Africa.[1] A significant proportion of the children in this study 
population had wasting and 25% were ex-premature infants. 
Asthma, anaemia, and cardiac abnormalities were the most prevalent underlying co-
morbidities. Unlike the study by Chisti et al., [13] in the present study an underlying 
cardiac abnormality was not a contraindication for the use of HFNC despite very 
limited evidence for its efficacy in paediatric cardiac patients, as shown by Testa et 
al.[15][14] One child with a cardiac abnormality died, but not whilst receiving the 
intervention. Although the numbers were small, HFNC was successfully used in 4 
children with underlying congenital heart disease as respiratory support during an 
acute admission for pneumonia. 
 
The proportion of HIV-infected children was significantly lower in the HFNC- 
availability group; this may reflect, although unlikely, the effectiveness of ongoing 
strategies to prevent perinatally acquired HIV infection in South Africa via PMTCT, 
and the early initiation of cART. 
HFNC use did not appear to impact on the number of deaths in the two groups, a 
finding consistent with that reported by Chisti et al. [13] Mortality rates were very low 
for the groups (0.2 and 0.3 deaths/100 admissions), therefore this study was 
underpowered to make any meaningful conclusions with regard to the effect of 
HFNC on mortality.	
Transferring children from L2 to L3 hospitals causes significant strain on limited 
resources, including the emergency medical services and L3 bed capacity. Whether 
a transfer is warranted and safe raises anxiety and concern among staff at the 
referring facility. A much higher proportion of children required additional respiratory 
support in the year when HFNC was available (14% vs 6.5%). It is possible that this 
was due to a very “bad respiratory season” (anecdotal). It is unlikely that this was 
simply due to availability of HFNC, as the intervention had been available at the L3 
facility in the preceding years, and criteria were the same for both institutions as to 
requirements for additional respiratory support, and children identified as needing 
the intervention would have been transferred. The transfers would not have been 
accepted by the tertiary institute if deemed unnecessary, and all decisions were 
consultant led. In cases of severe acute asthma, it can be postulated that use of 
HFNC may be adjunctive to the use of intravenous medication and nebulised 
medication as per protocol, but this made up a small part of the sample. Therefore, 
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almost two-thirds of the children who would potentially have been transferred prior to 
the availability of HFNC at L2 were successfully managed at L2 in 2016, reducing 
staff anxiety about observing and transferring very ill children, and decreasing the 
strain on the emergency medical services and L3 bed capacity. 
A significantly lower proportion of children transferred after receiving initial HFNC at 
L2 needed non-invasive or invasive respiratory support at L3 once transferred, 
compared with children transferred on/after receiving only standard LFNC oxygen. 
This supports study the findings of Wing et al.,[16][15] that that the introduction of 
HFNC reduced the need for intubation and reduced the need for non-
invasive/invasive retrieval during inter-hospital transfer. Because we used 
retrospective data from the pre-HFNC-availability cohort, we do not have information 
on how long children were at the referring facility prior to transfer and whether this 
could have impacted on outcome. Fewer children requiring high care/PICU non-
invasive or invasive ventilatory support at L3 also reduces the strain on L3 
resources (high care and PICU bed capacity and nursing requirements), justifying 
availability at lower levels of care. In the HFNC-availability group, the majority of 
children assessed to need support more than HFNC (i.e., those who did not meet 
the requirements of the protocol for safe use of HFNC at L2) ultimately required 
either CPAP or IPPV at L3. These findings support the current clinical practice and 
substantiate the current protocol. 
The NSH HFNC standard operating protocol indicates that if there is no objective 
response to HFNC oxygen, with reduction in HR and RR, this should be deemed a 
failure and necessitates transfer. The median time of receiving HFNC oxygen was 
12 h; this may indicate that this protocol was not strictly adhered to, and an earlier 
decision to transfer may have been preferable. It could also reflect natural disease 
progression with some patients deteriorating early in the admission, requiring 
increased support (including positive end expiratory pressure) because of hypoxia. 
The absence of any recorded serious adverse events related to the use of HFNC in 
our general paediatric ward is encouraging and concurs with the literature reporting 
few adverse effects.[15,17,18][14,16,17] This further supports use as an attractive option 
but requires strict adherence to protocol. 
Although reviewed, detailed analysis of the group of children that failed HFNC at L2 
was not done as we did not have the corresponding data from children who did not 
fail, for comparison. However, there appeared to be an association between the 
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doctors’ assessment of RR at initiation of HFNC and the documented RR at transfer 
(these patients remained significantly tachypnoeic). 
The high proportion of adenovirus positive NPAs in a group of infants with severe 
pneumonia needing more than HFNC supports the recently published study by 
Zampoli et al.[19][18] showing adenovirus as a potentially important cause of severe 
pneumonia necessitating ICU admission and resulting in persistent lung disease in 
young children in South Africa.   
 
Study limitations 
This study has several limitations. This was a retrospective design using an 
unmatched, historical comparator group. However, the criteria for additional 
respiratory support were the same and the staff was unchanged. Although the time 
period was similar (including one autumn/winter respiratory season in both groups) 
and the referral areas and admission criteria were the same, it seems that there 
were more admissions in the first group and that the severity of illness necessitating 
additional respiratory support was greater in the second group. The analysis of the 
group of children that failed HFNC at L2 was not detailed as we did not have 
corresponding data from children who did not fail, for comparison. 
 
Conclusions and recommendations 
HFNC is a safe, effective, feasible option for non-invasive respiratory support in a 
relatively resource limited setting as an adjunct in management of respiratory 
illnesses in children, with clinical improvement with reduced work of breathing and 
respiratory rates in those children who were successfully managed in a general 
paediatric ward. The lack of serious adverse events is encouraging but there is a 
need to refine recognition of early failures and to avoid delays in transfer. A detailed 
cost analysis was not done, but, despite the relative cost of disposables and 
equipment, broader cost reductions are anticipated: Decreased inter-hospital 
transfers, avoidance of L3 admissions and reduced bed pressure in a setting known 
to have a shortage of PICU and high care space.  
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Figure Legend 
 
Figure 1. Participant flow 
a Number of admissions for children ≥ 5 years old not available (89% of the overall 
cohort was <5 years old). 
NP, nasal prong; HFNC, high flow nasal cannula; L3, level 3 hospital; NSH, New 
Somerset Hospital; CPAP, continuous positive airway pressure; IPPV, intermittent 
positive pressure ventilation. 
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Table 1: Demographic and clinical characteristics 
  Total 
(n=120) 
Pre-HFNC-
availability group 
(n=54) 
HFNC-availability 
group 
(n=66) 
P 
Age, 
months 
 5.0 (1.9; 14.6) 3.2 (1.4; 13.2) 6.4 (2.5; 14.9) 0.057 
Age <5 y   107 (89.2) 47 (87) 60 (90.9) 0.49 
Sex Male 68 (56.7) 32 (59.3) 36 (54.6) 0.60 
 Female 52 (43.4) 22 (40.7) 30 (45.4)  
Nutritional 
status 
WAZa -0.98 ± 1.96 -1.38 ± 1.90 -0.65 ± 1.97 0.04 
 WAZ <-2a 37 (30.8) 23 (42.6) 14 (21.2) 0.01 
 HAZb -0.53 (-1.57; 0.28) -0.53 (-1.56; -0.02) -0.48 (-1.57; 0.57) 0.69 
 HAZ <-2 b 22/114 (19.3) 9/48 (18.8) 13/66 (19.7) 0.90 
 WHZ -0.60 (-1.38; 0.86) -1.17 (-2.09; 0.60) -0.23 (-0.88; 0.92) 0.002 
 WHA <-2 16/106 (15.1) 14/45 (31.1) 3/61 (3.3) <0.001 
HIV status Exposed 23 (19.2) 13 (24.1) 10 (15.2) 0.02† 
 Infected 10 (8.3) 8 (14.8) 2 (3.0)  
 Uninfected 87 (72.5) 33 (61.1) 54 (81.8)  
Co-
morbidities 
Anaemia 10/58 (17.2) 3/29 (10.3) 7/29 (24.1) 0.14† 
 Asthma 14/58 (24.1) 5/29 (17.2) 9/29 (31.0)  
 CLD 4/58 (6.9) 3/29 (10.3) 1/29 (3.5)  
 HIV infected 10/58 (17.2) 8/29 (27.6) 2/29 (6.9)  
 Cardiac 7/58 (12.1) 5/29 (17.2) 2/29 (6.9)  
 Probable TB 4/58 (6.9) 1/29 (3.5) 3/29 (10.3)  
 Other 9/58 (15.5) 4/29 (13.8) 5/29 (17.2)  
Prematurity  30 (25) 18 (33.3) 12 (18.2) 0.057 
Diagnosis Pneumonia 84 (70) 42 (77.8) 42 (63.6) 0.13† 
 Bronchiolitis 23 (19.2) 6 (11.1) 17 (25.8)  
 Asthma 13 (10.8) 6 (11.1) 7 (10.6)  
Data presented as n (%) or median (interquartile range) unless otherwise stated.  
a mean ± standard deviation; b total n=114, Pre-HFNC group n=48; c HFNC-group n=66; total 
n=106, Pre-HFNC group n=45; HFNC-group n=61  
† Fisher’s exact test.  
HFNC, high flow nasal cannula oxygen therapy; WAZ, weight-for-age z-score; HAZ, height 
(or length) for age z-score; WHZ, weight-for-height (or length) z-score; SD, standard 
deviation; HIV, human immunodeficiency virus; CLD, chronic lung disease; TB, tuberculosis. 
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Introduction 
Acute severe respiratory infections remain a major cause of mortality and morbidity in South 
Africa1, and globally (13%) 1-2A recent review of under-5 deaths in children in the Metro 
West geographical service area of the Western Cape Province showed pneumonia (25%) was 
the leading cause of death followed by gastro-enteritis (10%), prematurity (9%) and injuries 
(9%)3. 
Early and appropriate treatment of pneumonia can reduce morbidity and mortality4. 
Comprehensive guidelines have been developed, including recommendations contained in 
the IMCI strategy and South African Thoracic Society (SATS) guidelines5. Both guidelines take 
into account the high prevalence of HIV infection in South Africa and its impact on childhood 
pneumonia. Appropriate and rational antibiotic use, supportive care and standard low flow 
oxygen delivery (nasal prongs or face mask) form part of these guidelines5-6. 
However, in resource-limited developing countries, mortality from severe disease (related to 
hypoxemia and respiratory failure) remains high despite implementation of guidelines. 
Advanced respiratory support is central to the care of critically ill children but is often not an 
option in resource-limited settings7. 
Recently there has been increased interest in, and use of, non-invasive ventilation (NIV) 
within and outside the pediatric ICU8. While there has been increased focus on non-invasive 
ventilation options (in multiple forms), there is a paucity of literature to support the use of 
this intervention in children, and more specifically in sub-Saharan Africa. Continuous positive 
airway pressure ventilation (CPAP) in various forms has been used in neonatal care across 
the world including developing countries for many years. Studies show the technology is 
much less expensive, has lower complication rates, and requires less technical skill than 
mechanical ventilation, making it an attractive option in resource-limited countries.9-11 
Findings from research undertaken in Ghana showed that nurses in developing countries can 
successfully and safely apply CPAP after receiving appropriate training. The researchers 
found that CPAP decreases respiratory rate in children presenting with severe respiratory 
distress and was well tolerated and without complications12. 
Alongside CPAP the use of high flow nasal cannula oxygen (HFNC) devices in clinical settings 
is rapidly growing. These devices are being applied to patients across age groups in a variety 
of disease conditions. The mechanisms through which these devices affect the respiratory 
system and alter gas exchange are still under investigation but a growing body of evidence is 
supporting the mechanisms of action for HFNC to be five-fold: 
1) HFT provides for washout of nasopharyngeal dead space, which contributes to 
establishing improved fraction of alveolar gases with respect to carbon dioxide as well as 
oxygen13. 
2) The distensibility of the nasopharynx provides significant resistance on inspiratory relative 
to expiratory efforts. HFT provides adequate flow rates to match inspiratory flow and thus 
markedly attenuates the inspiratory resistance associated with the nasopharynx, and thus 
eliminates related work of breathing14. 
51
 
3) The provision of adequately warmed and humidified gas to the conducting airways 
improves conductance and pulmonary compliance compared to dry, cooler gas15. 
4) The provision of adequately warmed and humidified gas through the nasal pharynx 
reduces the metabolic work associated with gas conditioning and, 
5) High flow through the nasopharynx can be titrated to provide positive distending pressure 
for lung recruitment16. 
HFNC therapy can potentially improve outcomes such as reduced need for intubation and 
invasive ventilation.17-19 HFNC is readily applied and is not resource or cost intensive. Staff 
can easily be trained in the application of HFNC therapy and in the care of children using this 
therapy. It may also reduce the length of intubation, as HFNC holds potential to transition 
between extubation and low-flow nasal cannula oxygen delivery. An additional advantage is 
that children requiring this therapy may be cared for outside of the pediatric intensive care 
unit (PICU) or centralized high care unit, reducing pressure on scarce resources. Other 
potential advantages in resource-limited services include reduced stress for parents when 
children require transfer, reduced demand on emergency paramedic services required for 
transfers, and reduced anxiety for the initial hospital staff related to difficult decisions 
regarding whether transfer for NIV is indicated. 
Complications and serious adverse events that have been described with HFNC use include 
abdominal distension, pneumothorax, undetected clinical deterioration, blockage with nasal 
secretions and pressure necrosis20-21 
The recent donation of two HFNC devices to the general pediatric ward of New Somerset 
Hospital (NSH), a regional hospital in the Metro West sub-district of Cape Town afforded the 
pragmatic opportunity to review this new intervention.  
We propose a retrospective descriptive study of all children initiated on HFNC in the first 
year of availability of the intervention at NSH. 
 Pimary aim will be to: 
a) Describe the paediatric patients who qualified by standard protocol for HFNC 
oxygen, and their outcome 
b) Describe the incidence of serious adverse events (SAE) associated with this new 
intervention at regional level and compare this with available local and international 
data. 
Secondary aim is: 
Compare the number of children transferred to tertiary care for further non-
invasive/Invasive ventilation with the number of transfers in the year prior to 
availability of HFNC oxygen. 
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Our findings will inform our current local practice and potentially provide evidence to 
support introduction of this intervention in similar setting in South Africa and other resource 
limited settings 
Purpose of Study: 
We aim to document the first year of use of high flow nasal cannula(HFNC)oxygen support in 
hospitalized children younger than 13 years of age with respiratory distress at New 
Somerset Hospital(NSH), a regional level hospital in the Cape Town Metro, South Africa. 
The study will aim to: 
 Describe the paediatric patients who qualified by standard protocol for HFNC 
oxygen. 
 Compare the number of children transferred to tertiary care for further non-
invasive/Invasive ventilation with the number of transfers prior to availability of 
HFNC oxygen. (Was there a significant reduction in the need for transfer,indirectly 
reducing the load on tertiary services ,emergency medical services and caregiver 
distress  related to transfer and access to the tertiary centre?) 
 Describe the incidence of serious adverse events(SAE) associated with this new 
intervention at regional level and compare this with available local and international 
data.(Is the intervention safe?) 
Background:  
Methodology: 
Study design:  
A retrospective descriptive study of all children initiated on HFNC in the first year of 
availability of the intervention at NSH. A comparison will be made with children who 
required additional respiratory support and transfer in the year preceding inititation.   
Study population: 
The following children younger than 13 years of age will be included: 
 All children commenced on HFNC oxygen according to standard indication and 
standard operating procedure(S.O.P) at NSH from 1 August 2015 to 31 July 
2016.(Identified from the ethics approved NSH High Flow Nasal Cannulae Registry 
R051/2015).Sample size will be determined at end of study period(August 2016)-
estimated 30-40 patients 
 
 Chidren <13 years transferred to level 3 /tertiary care for respiratory support over a 
period of 12 months prior to the availability of HFNC oxygen therapy at 
NSH.(Patients identified from existing Morbidity and Mortality records in  the 
Department of Paediatrics NSH).Sample size:approximately 50 patients. 
 
53
Objectives : 
Child: 
Primary 
Describe the paediatric patients who qualified by standard protocol/S.O.P for HFNC 
oxygen support by: 
 Demographics: Age, Gender, Gestational age at birth/Birth weight 
 Nutritional status(WHO classification – normal, moderate or severe malnutrition 
based on Z-scores) 
 HIV status (HIV –exposed, uninfected, HIV negative, HIV infected on ARVs, HIV 
infected not on ARVs) 
 Diagnosis 
 Any underlying chronic illness 
 Length of time receiving HFNC 
 Outcome (demised, weaned successfully and discharged, transfer to L3, any SAE) 
 
Secondary 
Document the incidence and type of SAE and compare with available data(Local and 
international). 
SAE include: 
1. Gastric distension with/without aspiration 
2. Nasal Pressure sores/necrosis 
3. Blocked prongs secondary to secretions 
4. Pneumothorax 
 
Service/System 
Primary 
Compare the number of children transferred to tertiary care for further non-
invasive/Invasive ventilation with the number of transfers prior to availability of HFNC 
oxygen at this regional hospital. (Was there a significant reduction in the need for 
transfer,indirectly reducing the load on tertiary services ,emergency medical services 
and caregiver distress  related to transfer and access to the tertiary centre?) 
 
Secondary 
Study the incidence of SAE and compare with available data(international).This may 
indicate a need for improved training for health personal involved in children’s care. 
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Methods: 
Data collection: 
The NSH HFNC registry data will be available to the principle investigator(PI).The folders of 
all identified patients will be requested and drawn from medical records at NSH and will be 
reviewed by the PI for additional data. Each entry will record : 
 Age 
 Gender 
 GA at birth/Birth weight 
 Current nutrition status(WHO Z-scores) 
 HIV status 
 Diagnosis 
 Duration receiving HFNC 
 Outcome:  failed HFNC(transfer  to level 3 hospital for further non-invasive(CPAP) or 
invasive support(intubation and IPPV), death, successful weaning 
 Serious adverse events recorded while receiving HFNC oxygen therapy. 
 Nutritional status(WHO classification – normal, moderate or severe malnutrition) Z-
scores) 
 HIV status (HIV –exposed, uninfected, HIV negative, HIV infected on ARVs, HIV 
infected not on ARVs) 
 Diagnosis 
 Any underlying chronic illness 
 Length of time receiving HFNC 
 Outcome (demised, weaned successfully and discharged, transfer to L3, any SAE) 
Available existing morbidity data for  the 12 month period preceding the study period will be 
reviewed recording: 
 Number of children transferred for respiratory support over a period of 12 
months prior to introduction of HFNC oxygen therapy. 
 Number of children transferred for respiratory support over the period of 12 
months since the introduction of HFNC oxygen therapy. 
 
Data will be directly entered on an electronic data collection database(Microsoft Access). 
 
Data will be analysed by a UCT statistician using appropriate descriptive and comparative 
statistics. Analysis will be using STATA®. 
 
55
 
Ethics: 
In order to maintain confidentiality each entry will receive a study number and the data 
collated onto the data collection forms will only bear this study number. The principle 
researcher however will retain a copy of folder numbers correlated with study numbers so 
that a folder could be located again through medical records should it be necessary.This will 
be an electronic list,kept in password encrypted folder.No published data will be linked to a 
specific patient. 
HIV results will be obtained from the folders, for which consent (as per hospital guidelines) 
will have been obtained by the clinician involved in care and management and the parents 
duly counseled. 
It will not be possible to obtain individual consent from the parents of each child involved 
because of the retrospective design, but management is not influenced or altered by the 
study. Consent for the use of medical records will be obtained from the hospital CEOs of 
NSH and Red Cross Hospital with application to waive individual consent. 
Risks to participants: There are no risks to the participants as this is a retrospective study. 
Benefits to participants: There are no direct benefits to the patients in this study. However 
management guidelines at the local institution may be improved depending on results 
Reporting and implementation: 
All results of data analysis will be reported back to the paediatric department of New 
Somerset hospital with the potential to improve future management. 
Budget: 
The study will be undertaken by the principal researcher as part of her MMED project under 
the University of Cape Town. There will be no personal compensation for the principal 
researcher or the supervisor. Only routine existing equipment available at New Somerset 
Hospital will be required. 
Expenses related to printing and internet will be covered by funding through the 
postgraduate committee allocated to training registrars research projects (R5000/student). 
This will be managed from the supervisors entity for incidental costs. Statistical support will 
be from the University allocated statistician at no additional cost 
Strengths and limitations: 
The study is limited by its retrospective nature -the accuracy of recorded notes and the 
availability of the required folders from medical records may impact on data collection and 
validity. 
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COMPONENT:  
Child and Newborn Services 
NEW SOMERSET HOSPITAL 
 
 
CLINICAL PROTOCOL/GUIDELINE 
         page 1 of 4 
   
Protocol/Guideline Name: NASAL HIGH FLOW PRONG OXYGEN GUIDELINE 
 
Date of first issue:   5   /   12   / 2014   Revision 03 /11/ 2015 
Date for review:   5/12/2016 
 
Main author: ML Cooke 
Adapted for local use from: 
Royal Children’s Hospital Melbourne NHF Oxygen guideline 
 
NASAL HIGH FLOW  OXYGEN GUIDELINE 
Preamble 
Humidified high flow nasal prong (cannula) oxygen therapy is a method for providing oxygen 
and continuous positive airway pressure (CPAP) to children with respiratory distress.  It is used for 
the same indications as the traditional method of CPAP using a nasopharyngeal tube. HFNP 
may reduce need for NCPAP/intubation, or provide support post extubation. At high flow of 2 
litres per kg per min, using appropriate nasal prongs, a positive distending pressure of 4-8 
cmH2O is achieved.  This improves functional residual capacity thereby reducing work of 
breathing. Because flows used are high, heated water humidification is necessary to avoid 
drying of respiratory secretions and for maintaining nasal cilia function. 
INDICATIONS 
 
HFNP are used for the same indications as the traditional method of CPAP using a 
nasopharyngeal tube. At NSH the usual clinical scenarios would include: 
 Respiratory distress from bronchiolitis or pneumonia  or acute severe asthma 
 Respiratory distress from congestive heart failure 
 Respiratory support to children with neuromuscular disease 
Although additional indications include apnoea and support of the very small baby with 
respiratory distress, at NSH we will limit use to children above 3 kgs and will be temporary in 
apnoea- babies with recurrent apnoea should be transferred to Red Cross, as should babies 
under 3 kgs with significant respiratory distress to be closer to ICU/additional respiratory support. 
 
 High flow can be used if there is hypoxaemia (SpO2<90%) and signs of moderate to 
severe respiratory distress despite standard flow oxygen. 
 
Contraindications: 
 Blocked nasal passages/co anal atresia 
 Trauma/surgery to nasopharanyx 
Serving the Community 
APPENDIX 4: NSH SOP for use of HFNC
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EQUIPMENT  
 
 Oxygen source WITH Flow meter(no blender or humidifier) 
 Humidifier (Fisher and Paykel® MR850) with circuit tubing to attach to humidifier 
o Doctor will select if infant or adult pack depending on weight to match prongs 
o <12kg: infant, >12 kg adult 
 1 litre vacolitre bag of  water for irrigation (for humidifier) 
 Nasogastric tube 
 Nasal cannula (prongs) to attach to humidifier circuit tubing (size to fit nares 
comfortably) 
o Infants and children up to 12kg: OPT316 Infant (max flow 20L/min) or up to 
12.5kg: OPT318 Paediatric cannula (max flow 25L/min)  
o Children >12 kg: Adult cannula size S OPT542, size M OPT544, size L OPT546 
. 
SET UP OF EQUIPMENT  
 Setup by attending doctor 
 Select appropriate size nasal cannula and circuit/humidifier tubing for patient 
size(<14kg – paeds circuit and prongs, >14 kg – adult circuit and prongs)  
 Hold bottom arrow down for 5 seconds to change from paeds to adult mode  
 Connect nasal cannula to adaptor on circuit tubing, and connect circuit tubing to 
humidifier 
 Connect oxygen tubing to back of humidifier from the wall(no blender or humidifier) 
 Attach 1 litre “water for irrigation” bag to humidifier on machine and turn on to 34ºC.  
The water bag must run freely and be placed as high as possible above the humidifier 
to achieve flow of water into the humidifier chamber. Do not fill from a bottle. The 
system is then ready for use. 
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PATIENT MANAGEMENT 
 Insert NGT 
 Clean cheeks with unisolve or friars balsam and ensure DRY 
 Secure nasal cannula on patient using supplied granuflex  "wiggle pads™", ensuring the 
prongs sit well into the nares  DO NOT CUT PRONGS SHORTER 
 attach to the cheekbones to avoid dislodgement 
 prongs should not totally occlude nares- should occlude ½- 2/3 of nostrils 
 if not sitting well, remove at VELCRO level(not granuflex off skin) and reattach 
 let the prongs hang down loosely over chest,   DO NOT PUT BEHIND EARS 
START THE HIGH FLOW NASAL CANNULA SYSTEM AT THE FOLLOWING SETTINGS: 
 Flow rate :calculated by prescribing doctor 
 ≤10Kg  2 L per kg per minute 
 >10Kg  2 L per kg per minute for the first 10kg + 0.5L/kg/min for each kg above that (max 
flow 50 L/min) 
 Usually start off at 6L/min and increase by 2l/min every 1-2minutes up to goal flow rate 
over a few minutes to allow patient to adjust to high flow. 
 If weight between 3-5kg start at 4l/min, increase by 1l/min 
 FiO2 
 Adjust wall flow rate and read concentration of oxygen being delivered off machine 
and adjust accordingly 
 Start at 50-60% for bronchiolitis and respiratory distress 
 Target range for SpO2 of 94%-98% (not in cyanotic congenital heart disease) 
 If the child needs a neb put over the prongs   
PATIENT MONITORING 
Monitor patient for response 
 Respiratory rate and Heart rate 
 Degree of chest in-drawing 
 SpO2 
Within 2 hours it should be possible to reduce the FiO2 and clinical stabilisation should be seen 
 The FiO2 required to maintain SpO2 in the target range should decrease to <40% 
 The heart rate and respiratory rate should reduce by 20% 
 Chest in drawing and other signs of respiratory distress should improve 
Urgent review for transfer +/- intubation if any of the following occurs: 
 The patient is not stabilising as described above 
 The degree of respiratory distress worsens 
 Hypoxaemia persists despite high gas flow 
 Persistent requirement for >50% oxygen 
 Note that on high flow if high FiO2 is used, oxygen saturation may be maintained in an 
infant despite the development of hypercarbic respiratory failure 
 If there is rapid deterioration of oxygen saturation or marked increased work of 
breathing, a chest x-ray should be done to exclude a pneumothorax 
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PATIENT NURSING CARE  
 Infants on high flow should preferably have a nasogastric tube 
 Aspirate the NG 2-4 hourly for air if abdominal distension 
 Oral and nasal care must be performed 2-4 hourly 
 Note nasal prongs are in correct position and no pressure areas to nares 
 Spare "wiggle pads™" available to change as required to ensure prongs secure 
 Gentle suction as required to keep nares clear 
 Check humidifier water level hourly 
 Documentation:  NHF(nasal high flow) chart 
o hourly : Flow rate, FiO2 & humidifier temp: off machine NOT wall flow meter 
o Document RR,HR, SpO2  
 Once stable on high flow, the infant should be assessed by a doctor as to whether they 
can feed.  Some infants can continue to breast feed or cup feed, but most require 
feeding via a nasogastric tube, at least for first 24 hours 
WEANING OF HIGH FLOW NASAL CANNULA OXYGEN 
Start weaning when the child's clinical condition is improving as indicated by: 
 Decreased work of breathing 
 Normal or improved respiratory rate 
 Return to normal cardiovascular parameters 
For infants <10Kg 
 The first step is to wean the FiO2 to <40% (usually within the first 1-2 hours, as above) 
 Reduce flow gradually by 1- 2l/min 
 Once flow down to  5 L/min then change to standard low flow titrated oxygen (1 to 
2L/min) or cease oxygen therapy if stable 
For children >10Kg  
 Wean FiO2 to 40% 
 Once the indication for using high flow has resolved, and the patient is stable in 40% 
oxygen the flow can be weaned to 1-2 L/min with  FiO2 of 100% then switch to via 
standard nasal prong therapy, or cease  oxygen therapy 
Generally there is no need for a prolonged weaning process, better to be on high flow, 
standard low flow or off oxygen therapy. 
Keep HF nasal prongs in packet next to patient should they require use again 
DO NOT THROW AWAY UNTIL PATIENT DISCHARGED 
Complications 
Gastric distension 
Pressure areas 
Blocked HFNP due to secretions 
Pneumothorax 
STERILIZE WITH RED TUBING THAT IS PROVIDED WITH THE MACHINE according to instructions -
55MINUTE CYCLE,DO NOT SEND AWAY.PUT RED TUBE BACK IN BLACK BAG AFTER CYCLE 
COMPLETE 
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ISSN 0256-9574 printed version 
ISSN 2078-5135 online version 
INSTRUCTIONS TO AUTHORS 
 Scope and policies 
 Conflict of interest 
 Manuscripts preparation 
 Manuscripts submission 
  
Scope and policies 
 
The SAMJ is a monthly, peer–reviewed, internationally 
indexed, general medical journal publishing leading research 
impacting clinical care in Africa. The Journal is not limited to 
articles that have ‘general medical content’, but is intending 
to capture the spectrum of medical and health sciences, 
grouped by relevance to the country’s burden of disease. 
This will include research in the social sciences and 
economics that is relevant to the medical issues around our 
burden of disease. 
The journal carries research articles and letters, editorials, 
clinical practice and other medical articles and personal 
opinion, South African health–related news, obituaries, 
general correspondence, and classified advertisements (refer 
to the section policies for further information). 
 
  
Conflict of interest 
 
Conflicts of interest can derive from any kind of relationship 
or association that may influence authors’ or reviewers’ 
opinions about the subject matter of a paper. The existence 
of a conflict – whether actual, perceived or potential – does 
not preclude publication of an article. However, we aim to 
ensure that, in such cases, readers have all the information 
they need to enable them to make an informed assessment 
about a publication’s message and conclusions. We require 
that both authors and reviewers declare all sources of 
support for their research, any personal or financial 
relationships (including honoraria, speaking fees, gifts 
received, etc) with relevant individuals or organisations 
connected to the topic of the paper, and any association with 
a product or subject that may constitute a real, perceived or 
potential conflict of interest. If you are unsure whether a 
specific relationship constitutes a conflict, please contact the 
editorial team for advice. If a conflict remains undisclosed 
and is later brought to the attention of the editorial team, it 
will be considered a serious issue prompting an investigation 
with the possibility of retraction. 
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Manuscripts preparation 
 
Preparing an article for anonymous review 
 
To ensure a fair and unbiased review process, all 
submissions are to include an anonymised version of the 
manuscript. The exceptions to this are Correspondence, 
Book reviews and Obituary submissions. 
Submitting a manuscript that needs additional blinding can 
slow down your review process, so please be sure to follow 
these simple guidelines as much as possible: 
 An anonymous version should not contain any author, 
affiliation or particular institutional details that will 
enable identification. 
 Please remove title page, acknowledgements, contact 
details, funding grants to a named person, and any 
running headers of author names. 
 Mask self–citations by referring to your own work in 
third person. 
General article format/layout 
 
Accepted manuscripts that are not in the correct format 
specified in these guidelines will be returned to the author(s) 
for correction, which will delay publication. 
General: 
 Manuscripts must be written in UK English. 
 The manuscript must be in Microsoft Word or RTF 
document format. Text must be single–spaced, in 12–
point Times New Roman font, and contain no 
unnecessary formatting (such as text in boxes). 
 Please make your article concise, even if it is below 
the word limit. 
 Qualifications, full affiliation (department, 
school/faculty, institution, city, country) and contact 
details of ALL authors must be provided in the 
manuscript and in the online submission process. 
 Abbreviations should be spelt out when first used and 
thereafter used consistently, e.g. 'intravenous (IV)' or 
'Department of Health (DoH)'. 
 Scientific measurements must be expressed in SI 
units except: blood pressure (mmHg) and 
haemoglobin (g/dL). 
 Litres is denoted with an uppercase L e.g. 'mL' for 
millilitres). 
 Units should be preceded by a space (except for % 
and °C), e.g. '40 kg' and '20 cm' but '50%' and 
'19°C'. 
 Please be sure to insert proper symbols e.g. π not u 
for micro, a not a for alpha, b not B for beta, etc. 
 Numbers should be written as grouped per thousand–
units, i.e. 4 000, 22 160. 
  
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 Quotes should be placed in single quotation marks: 
i.e. The respondent stated: '...' 
 Round brackets (parentheses) should be used, as 
opposed to square brackets, which are reserved for 
denoting concentrations or insertions in direct quotes. 
 If you wish material to be in a box, simply indicate 
this in the text. You may use the table format – this is 
the only exception. Please DO NOT use fill, format 
lines and so on. 
SAMJ is a generalist medical journal, therefore for articles 
covering genetics, it is the responsibility of authors to apply 
the following: 
 Please ensure that all genes are in italics, and 
proteins/enzymes/hormones are not. 
 Ensure that all genes are presented in the correct 
case e.g. TP53 not Tp53. 
**NB: Copyeditors cannot be expected to pick up and 
correct errors wrt the above, although they will raise 
queries where concerned. 
 Define all genes, proteins and related shorthand 
terms at first mention, e.g. ‘188del11’ can be glossed 
as ‘an 11 bp deletion at nucleotide 188.’ 
 Use the latest approved gene or protein symbol as 
appropriate: 
o Human Gene Mapping Workshop (HGMW): 
genetic notations and symbols 
o HUGO Gene Nomenclature Committee: 
approved gene symbols and nomenclature 
o OMIM: Online Mendelian Inheritance in Man 
(MIM) nomenclature and instructions 
o Bennet et al. Standardized human pedigree 
nomenclature: Update and assessment of the 
recommendations of the National Society of 
Genetic Counselors. J Genet Counsel 
2008;17:424–433: standard human pedigree 
nomenclature. 
Preparation notes by article type 
 Research 
 Editorials 
 CME 
 In Practice and Case reports 
 Reviews 
 Clinical trials 
 Correspondence 
 Obituaries 
 Book reviews 
 Guidelines 
Illustrations/photos/scans 
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 If illustrations submitted have been published 
elsewhere, the author(s) should provide consent to 
republication obtained from the copyright holder. 
 Figures must be numbered in Arabic numerals and 
referred to in the text e.g. '(Fig. 1)'. 
 Each figure must have a caption/legend: Fig. 1. 
Description (any abbreviations in full). 
 All images must be of high enough resolution/quality 
for print. 
 All illustrations (graphs, diagrams, charts, etc.) must 
be in PDF form. 
 Ensure all graph axes are labelled appropriately, with 
a heading/description and units (as necessary) 
indicated. Do not include decimal places if not 
necessary e.g. 0; 1.0; 2.0; 3.0; 4.0 etc. 
 Scans/photos showing a specific feature e.g. 
Intermediate magnification micrograph of a low 
malignant potential (LMP) mucinous ovarian tumour. 
(H&E stain). –include an arrow to show the tumour. 
 Each image must be attached individually as a 
'supplementary file' upon submission (not solely 
embedded in the accompanying manuscript) and 
named Fig. 1, Fig. 2, etc. 
Tables 
 Tables should be constructed carefully and simply for 
intelligible data representation. Unnecessarily 
complicated tables are strongly discouraged. 
 Large tables will generally not be accepted for 
publication in their entirety. Please consider 
shortening and using the text to highlight specific 
important sections, or offer a large table as an 
addendum to the publication, but available in full on 
request from the author. 
 Embed/include each table in the manuscript Word file 
– do not provide separately as supplementary files. 
 Number each table in Arabic numerals (Table 1, Table 
2, etc.) and refer to consecutively in the text. 
 Tables must be cell–based (i.e. not constructed with 
text boxes or tabs) and editable. 
 Ensure each table has a concise title and column 
headings, and include units where necessary. 
 Footnotes must be indicated with consecutive use of 
the following symbols: * † ‡ § ¶ || then ** †† ‡‡ etc. 
 
o Do not: Use [Enter] within a row to make 
‘new rows’: 
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o Rather: 
Each row of data must have its own proper 
row: 
 
o Do not: use separate columns for n and %: 
 
o Rather: 
Combine into one column, n (%): 
 
o Do not: have overlapping categories, e.g.: 
 
o Rather: 
Use <> symbols or numbers that don’t 
overlap: 
References 
 
NB: Only complete, correctly formatted reference lists in 
Vancouver style will be accepted. Reference lists must be 
generated manually and not with the use of reference 
manager software. Endnotes must not be used. 
 Authors must verify references from original sources. 
 Citations should be inserted in the text as superscript 
numbers between square brackets, e.g. These 
regulations are endorsed by the World Health 
Organization,[2] and others.[3,4–6] 
 All references should be listed at the end of the article 
in numerical order of appearance in the Vancouver 
style (not alphabetical order). 
 Approved abbreviations of journal titles must be 
used; see the List of Journals in Index Medicus. 
 Names and initials of all authors should be given; if 
there are more than six authors, the first three names 
should be given followed by et al. 
 Volume and issue numbers should be given. 
 First and last page, in full, should be given e.g.: 
1215–1217 not 1215–17. 
 Wherever possible, references must be accompanied 
by a digital object identifier (DOI) link). 
Authors are encouraged to use the DOI lookup service 
offered by CrossRef: 
o On the Crossref homepage, paste the article 
title into the ‘Metadata search’ box. 
o Look for the correct, matching article in the list 
of results. 
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o Click Actions > Cite 
o Alongside 'url =' copy the URL between { }. 
o Provide as follows, 
e.g.: https://doi.org/10.7196/07294.937.98x 
Some examples: 
 Journal references: Price NC, Jacobs NN, Roberts DA, 
et al. Importance of asking about glaucoma. Stat Med 
1998;289(1):350-355. 
http://dx.doi.org/10.1000/hgjr.182 
 Book references: Jeffcoate N. Principles of 
Gynaecology. 4th ed. London: Butterworth, 1975:96–
101. 
 Chapter/section in a book: Weinstein L, Swartz MN. 
Pathogenic Properties of Invading Microorganisms. In: 
Sodeman WA, Sodeman WA, eds. Pathologic 
Physiology: Mechanisms of Disease. Philadelphia: WB 
Saunders, 1974:457–472. 
 Internet references: World Health Organization. The 
World Health Report 2002 – Reducing Risks, 
Promoting Healthy Life. Geneva: WHO, 2002. 
http://www.who.int/whr/2002 (accessed 16 January 
2010). 
 
 Legal references 
 
o Government Gazettes: 
National Department of Health, South Africa. 
National Policy for Health Act, 1990 (Act No. 
116 of 1990). Free primary health care 
services. Government Gazette No. 
17507:1514. 1996. 
In this example, 17507 is the Gazette Number. 
This is followed by :1514 – this is the notice 
number in this Gazette. 
 
o Provincial Gazettes: 
Gauteng Province, South Africa; Department 
of Agriculture, Conservation, Environment and 
Land Affairs. Publication of the Gauteng health 
care waste management draft regulations. 
Gauteng Provincial Gazette No. 373:3003, 
2003. 
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o Acts: 
South Africa. National Health Act No. 61 of 
2003. 
 
o Regulations to an Act: 
South Africa. National Health Act of 2003. 
Regulations: Rendering of clinical forensic 
medicine services. Government Gazette No. 
35099, 2012. (Published under Government 
Notice R176). 
 
o Bills: 
South Africa. Traditional Health Practitioners 
Bill, No. B66B–2003, 2006. 
 
o Green/white papers: 
South Africa. Department of Health Green 
Paper: National Health Insurance in South 
Africa. 2011. 
 
o Case law: 
Rex v Jopp and Another 1949 (4) SA 11 (N) 
Rex v Jopp and Another: Name of the parties 
concerned 
1949: Date of decision (or when the case was 
heard) 
(4): Volume number 
SA: SA Law Reports 
11: Page or section number 
(N): In this case Natal – where the case was 
heard. Similarly, (C) woud indicate Cape, (G) 
Gauteng, and so on. 
NOTE: no . after the v 
 
 Other references (e.g. reports) should follow the 
same format: Author(s). Title. Publisher place: 
Publisher name, year; pages. 
 Cited manuscripts that have been accepted but not 
yet published can be included as references followed 
by '(in press)'. 
 Unpublished observations and personal 
communications in the text must not appear in the 
reference list. The full name of the source person 
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must be provided for personal communications e.g. 
'...(Prof. Michael Jones, personal communication)'. 
  
Manuscripts submission 
 
To submit an article: 
 Please ensure that you have prepared your 
manuscript in line with the SAMJ requirements. 
 All submissions should be submitted via Editorial 
Manager 
 The following are required for your submission to be 
complete: 
o Anonymous manuscript (unless otherwise 
stated) 
o Author Agreement form 
o Manuscript 
o Any supplementary files: figures, datasets, 
patient consent form, permissions for 
published images, etc. 
 Once the submission has been successfully processed 
on Editorial Manager, it will undergo a technical check 
by the Editorial Office before it will be assigned to an 
editor who will handle the review process. If the 
author guidelines have not been appropriately 
followed, the manuscript may be sent back to the 
author for correcting. 
Submission Preparation Checklist 
As part of the submission process, authors are required to 
check off their submission's compliance with all of the 
following items, and submissions may be returned to authors 
that do not adhere to these guidelines. 
1. Named authors consent to publication and meet the 
requirements of authorship as set out by the journal. 
2. The submission has not been previously published, 
nor is it before another journal for consideration. 
3. The text complies with the stylistic and bibliographic 
requirements in Author Guidelines. 
4. The manuscript is in Microsoft Word or RTF document 
format. The text is single–spaced, in 12–point Times 
New Roman font, and contains no unnecessary 
formatting. 
5. Illustrations/figures are high resolution/quality (not 
compressed) and in an acceptable format (preferably 
TIFF or PNG). These must be submitted individually 
as 'supplementary files' (not solely embedded in the 
manuscript). 
6. For illustrations/figures or tables that have been 
published elsewhere, the author has obtained written 
consent to republication from the copyright holder. 
11.  
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7. Where possible, references are accompanied by a 
digital object identifier (DOI) and PubMed ID 
(PMID)/PubMed Central ID (PMCID). 
8. An abstract has been included where applicable. 
9. The research was approved by a Research Ethics 
Committee (if applicable) 
10. Any conflict of interest (or competing interests) is 
indicated by the author(s). 
  
[Home] [About the journal][Editorial board] [Subscriptions] 
 
 All the content of the journal, except where otherwise noted, is licensed under a Creative 
Commons License 
Health & Medical Publishing Group 
South African Medial Journal, 28 Main Road, Rondebosch, 
Cape Town, Western Cape Province, ZA, 7700, 
Tel: +27 21 681 7200 
 
 
publishing@hmpg.co.za 
Research 
Guideline word limit: 4 000 words 
  
Research articles describe the background, methods, results and conclusions of an original 
research study. The article should contain the following sections: introduction, methods, 
results, discussion and conclusion, and should include a structured abstract (see below). The 
introduction should be concise – no more than three paragraphs – on the background to the 
research question, and must include references to other relevant published studies that 
clearly lay out the rationale for conducting the study. Some common reasons for conducting 
a study are: to fill a gap in the literature, a logical extension of previous work, or to answer 
an important clinical question. If other papers related to the same study have been 
published previously, please make sure to refer to them specifically. Describe the study 
methods in as much detail as possible so that others would be able to replicate the study 
should they need to. Results should describe the study sample as well as the findings from 
the study itself, but all interpretation of findings must be kept in the discussion section, 
which should consider primary outcomes first before any secondary or tertiary findings or 
post-hoc analyses. The conclusion should briefly summarise the main message of the paper 
and provide recommendations for further study. 
  
Select figures and tables for your paper carefully and sparingly. Use only those figures that 
provided added value to the paper, over and above what is written in the text. 
Do not replicate data in tables and in text . 
  
Structured abstract 
 This should be 250-400 words, with the following recommended headings: 
o Background: why the study is being done and how it relates to other published work. 
o Objectives: what the study intends to find out 
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o Methods: must include study design, number of participants, description of the intervention, 
primary and secondary outcomes, any specific analyses that were done on the data. 
o Results: first sentence must be brief population and sample description; outline the results 
according to the methods described. Primary outcomes must be described first, even if they 
are not the most significant findings of the study. 
o Conclusion: must be supported by the data, include recommendations for further 
study/actions. 
 Please ensure that the structured abstract is complete, accurate and clear and has been 
approved by all authors. 
 Do not include any references in the abstracts. 
  
  Here is an example of a good abstract. 
  
Main article 
All articles are to include the following main sections: Introduction/Background, Methods, 
Results, Discussion, Conclusions. 
The following are additional heading or section options that may appear within these: 
 Objectives (within Introduction/Background): a clear statement of the main aim of the study 
and the major hypothesis tested or research question posed 
 Design (within Methods): including factors such as prospective, randomisation, blinding, 
placebo control, case control, crossover, criterion standards for diagnostic tests, etc. 
 Setting (within Methods): level of care, e.g. primary, secondary, number of participating 
centres. 
 Participants (instead of patients or subjects; within Methods): numbers entering and 
completing the study, sex, age and any other biological, behavioural, social or cultural factors 
(e.g. smoking status, socioeconomic group, educational attainment, co-existing disease 
indicators, etc)that may have an impact on the study results. Clearly define how participants 
were enrolled, and describe selection and exclusion criteria. 
 Interventions (within Methods): what, how, when and for how long. Typically for randomised 
controlled trials, crossover trials, and before and after studies. 
 Main outcome measures (within Methods): those as planned in the protocol, and those 
ultimately measured. Explain differences, if any. 
  
Results 
 Start with description of the population and sample. Include key characteristics of comparison 
groups. 
 Main results with (for quantitative studies) 95% confidence intervals and, where appropriate, 
the exact level of statistical significance and the number need to treat/harm. Whenever 
possible, state absolute rather than relative risks. 
 Do not replicate data in tables and in text. 
 If presenting mean and standard deviations, specify this clearly. Our house style is to present 
this as follows: 
 E.g.: The mean (SD) birth weight was 2 500 (1 210) g. Do not use the ± symbol for mean 
(SD). 
 Leave interpretation to the Discussion section. The Results section should just report the 
findings as per the Methods section. 
  
Discussion 
Please ensure that the discussion is concise and follows this overall structure – sub-headings 
are not needed: 
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 Statement of principal findings 
 Strengths and weaknesses of the study 
 Contribution to the body of knowledge 
 Strengths and weaknesses in relation to other studies 
 The meaning of the study – e.g. what this study means to clinicians and policymakers 
 Unanswered questions and recommendations for future research 
  
Conclusions 
This may be the only section readers look at, therefore write it carefully. Include primary 
conclusions and their implications, suggesting areas for further research if appropriate. Do 
not go beyond the data in the article. 
  
Editorials 
Guideline word limit: 1 000 words 
  
These opinion or comment articles are usually commissioned but we are happy to consider 
and peer review unsolicited editorials. Editorials should be accessible and interesting to 
readers without specialist knowledge of the subject under discussion and should have an 
element of topicality (why is a comment on this issue relevant now?) There should be a 
clear message to the piece, supported by evidence. 
Please make clear the type of evidence that supports each key statement, e.g.: 
 expert opinion 
 personal clinical experience 
 observational studies 
 trials 
 systematic reviews. 
  
CME (by invite only) 
CME is intended to provide readers with practical, up-to-date information on medical and 
related matters. It is aimed at those who are not specialists in the field. 
From January 2016, all CME articles will be printed in full in the SAMJ. Please try to adhere 
strictly to the guidelines on word count as we have a page limit for the print issue of 
the SAMJ. We reserve the right to place some tables and reference lists online if this is 
necessary for space. 
In practice, this means that each CME topic usually covers two issues of the print issue of 
the SAMJ. 
  
The guest editor, in consultation with the editor, is responsible for convening a team of 
authors, deciding on the subjects to be covered and for reviewing the manuscripts 
submitted. The suggestion is for 4 - 5 articles, although there is some room for flexibility 
contingent on discussions with the editor. 
  
For queries about these guidelines please feel free to contact the CME editor, Dr Bridget 
Farham, by email (ugqirha@iafrica.com) or telephone (+27 (0)21 789 2331). 
  
Review process 
The guest editor reviews the articles and returns them to the CME editor for review and final 
approval. 
  
Guest editorials 
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Guideline word limit: 1 000 words 
 Include the guest editor’s personal details (qualifications, positions, affiliation, e-mail 
address, and a short personal profile (50words)). 
 If possible, include a photograph of the author(s) at high enough resolution for print. It is 
preferable to provide two guest editorials, one for each issue, so that the content of the 
articles in each issue is covered. 
  
Articles 
Guideline word limit: 2 000 - 3 000 words 
 Each article requires an abstract of ±200 words. 
 The editor reserves the right to shorten articles but will send a substantially shortened article 
back for author approval. 
  
Personal details 
Please supply: Your qualifications, position and affiliations and MP number (used for CPD 
points); Address, telephone number and fax number, and your e-mail address; and a short 
personal profile (50words)and a few words about your current fields of interest. 
  
In Practice 
Guideline word limit: 2 000 - 3 000words 
  
This section includes articles that would previously have been accepted into the Forum 
section, and case reports. 
In practice articles are those that draw attention to specific issues of clinical, economic or 
political interest regarding medicine and healthcare in southern Africa. They are assigned to 
a topic: 
  
 Case report 
 Clinical practice 
 Clinical alert 
 Issues in medicine 
 Issues in public health 
 Healthcare delivery 
 Consensus/Position statement 
 Medicine and the environment 
 Medicine and the law 
 Cochrane corner 
  
  
An In Practice article should follow the following format – sub-headings are not necessary, 
but may be used for clarity: 
 Author affiliations and qualifications: to be the same as for Research. Provide all authors’ 
names and initials, qualifications and full affiliations, and corresponding author. 
 Short abstract: does not need to be structured, but should capture the essential features of 
the article 
 Introduction: the reason for the article and the issue being addressed 
 Recent research, discussion, local policy around the issue – include your own research where 
appropriate 
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 All statements should be referenced and, if opinion only, this should be stated 
 Discussion: how this article adds to the discussion around a particular topic 
 If a clinical practice or policy point is at issue, this needs to be emphasised, using a box with 
highlights if appropriate. 
  
Essentially In practice is an opportunity for a more discursive approach to topics of clinical, 
economic or political importance in southern African health systems. It is not an opportunity 
to put forward unsubstantiated opinions! 
  
Case reports 
The SAMJ has recently started to accept case reports. The cases must come from Africa, 
preferably southern Africa unless the condition is common to all African countries, and must 
be either a completely new description of a clinical condition or result (use Google!) or a 
case that highlights important practice or management issues. 
  
Please use the following format for case reports: 
 Title of case: do not include the words ‘a case report’ in the title 
 Summary/abstract:  up to 150 words summarising the case presentation and outcome 
 Background: why is this case important and why did you write it up? 
 Case presentation: presenting features, medical, social, family history as appropriate 
 Case management: should be according to best practice, and if not, please explain why 
 Investigations, if relevant: save space by simply saying ‘normal’ if, for example, renal 
function was completely normal, rather than listing normal results, highlight the abnormal – 
or indeed the normal if this is clinically significant 
 Differential diagnosis, if relevant 
 Treatment, if relevant 
 Outcome and follow-up 
 Discussion – a VERY BRIEF review of similar published cases 
 Teaching points: 3 - 5 bullet points 
 References: as per the SAMJ house style 
 Tables and figures: keep to a minimum. Use clinical images where relevant – we need hi-res 
versions for print, and identifiable persons must have a consent form 
 Patient consent: please include a statement about patient consent to a written case report. 
This should be uploaded as a supplementary file. 
  
Clinical trials 
Guideline word limit: 4000 words 
  
As per the recommendations published by the International Committee of Medical Journal 
Editors (ICMJE), clinical trial research is any research that assigns individuals to an 
intervention, with or without a concurrent comparison/control group to study the cause-and-
effect relationship between the intervention and health outcomes. All clinical trials should be 
registered with the appropriate national clinical trial registry (or any international primary 
register, if relevant), and the trial registration number should be cited at the end of the 
abstract. Since 1st December 2005, all clinical trials conducted in South Africa have been 
required to be registered in the South African National Clinical Trials Register. The SAMJ therefore 
requires that clinical trials be registered in the relevant public trials registry at or before the 
time of first patient enrollment as a condition for publication. The trial registry name and 
registration number must be included in the manuscript. 
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Please refer to the general guidelines for all papers at the top of this article for additional 
requirements with respect to ethics approval, funding, author contributions, etc. The format 
of original research articles should be followed for reporting of clinical trial results. 
  
Review articles 
Guideline word limit: 4 000 words 
  
These are welcome, but should be either commissioned or discussed with the Editor before 
submission. A review article should provide a clear, up-to-date account of the topic and be 
aimed at non-specialist hospital doctors and general practitioners. 
  
Please ensure that your article includes: 
 Abstract: unstructured, of about 100-150 words, explaining the review and why it is 
important 
 Methods: Outline the sources and selection methods, including search strategy and keywords 
used for identifying references from online bibliographic databases. Discuss the quality of 
evidence. 
 When writing: clarify the evidence you used for key statements and the strength of the 
evidence. Do not present statements or opinions without such evidence, or if you have to, 
say that there is little or no evidence and that this is opinion. Avoid specialist jargon and 
abbreviations, and provide advice specific to southern Africa. 
 Personal details: Please supply your qualifications, position and affiliations and MP number 
(used for CPD points); address, telephone number and fax number, and your e-mail address; 
and a short personal profile (50 words) and a few words about your current fields of interest. 
  
Correspondence (Letters to the Editor) 
Guideline word limit: 500 words 
  
Letters to the editor should relate either to a paper or article published by the SAMJ or to a 
topical issue of particular relevance to the journal’s readership 
  
 May include only one illustration or table 
 Must include a correspondence address. 
  
Book reviews 
Guideline word limit: 400 words 
Should be about 400 words and must be accompanied by the publication details of the book. 
Provide a hi-res image of the cover if possible (with permission from the copyright holder). 
  
Obituaries 
Guideline word limit: 400 words 
Should be offered within the first year of the practitioner’s death, and may be accompanied 
by a photograph. 
  
Guidelines  
Guidelines should always be discussed with the Editor prior to submission. 
  
Because of the intensive review process required to ensure Guidelines are independent, 
evidence-based and free from commercial bias, they are usually published as a supplement 
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to the SAMJ, the costs of which must be covered by sponsorship, advertising or payment by 
the guideline authors/association. We will provide a quote based on the expected length of 
the guideline and whether it is to appear online only, or in print, which must be accepted by 
the body putting the guidelines together before submitting the work to the SAMJ. 
  
The Editor reserves the right to determine the scheduling of supplements. Understandably, 
a delay in publication must be anticipated dependent upon editorial workflow. 
All guidelines should include a clear, transparent statement about all sources of funding and 
an explicit, clear statement of conflicts of interest of any of the participants in the guidelines 
about industry funding for lectures, research, conference participation etc.  
All guidelines should be structured according to Agree II. 
Please access this website before putting the guidelines together, download the Agree 11 
instrument and use this to put the guidelines together. 
All submitted guidelines will be sent to the local Agree II appraisal committee for review and 
must be endorsed by an appropriate body prior to consideration and all conflicts of interest 
expressed. 
  
A structured abstract not exceeding 400 words (recommended sub-headings: Background, 
Recommendations, Conclusion) is required. Sections and sub-sections must be numbered 
consecutively (e.g. 1. Introduction; 1.1 Definitions; 2.etc.) and summarised in a Table of 
Contents. 
  
Illustrations/photos/scans 
 If illustrations submitted have been published elsewhere, the author(s) should provide 
consent to republication obtained from the copyright holder. 
 Figures must be numbered in Arabic numerals and referred to in the text e.g. '(Fig. 1)'. 
 Each figure must have a caption/legend: Fig. 1. Description (any abbreviations in full). 
 All images must be of high enough resolution/quality for print. 
 All illustrations (graphs, diagrams, charts, etc.) must be in PDF or jpeg form. 
 Ensure all graph axes are labelled appropriately, with a heading/description and units (as 
necessary) indicated. Do not include decimal places if not necessary e.g. 0; 1.0; 2.0; 3.0; 4.0 
etc. 
 Scans/photos showing a specific feature e.g. Intermediate magnification micrograph of a low 
malignant potential (LMP) mucinous ovarian tumour. (H&E stain). –include an arrow to show 
the tumour. 
 Each image must be attached individually as a 'supplementary file' upon submission (not 
solely embedded in the accompanying manuscript) and named Fig. 1, Fig. 2, etc. 
  
Tables 
 Tables should be constructed carefully and simply for intelligible data representation. 
Unnecessarily complicated tables are strongly discouraged. 
 Large tables will generally not be accepted for publication in their entirety. Please consider 
shortening and using the text to highlight specific important sections, or offer a large table as 
an addendum to the publication, but available in full on request from the author 
 Embed/include each table in the manuscript Word file - do not provide separately as 
supplementary files. 
 Number each table in Arabic numerals (Table 1, Table 2, etc.) and refer to consecutively in 
the text. 
 Tables must be cell-based (i.e. not constructed with text boxes or tabs) and editable. 
 Ensure each table has a concise title and column headings, and include units where 
necessary. 
81
 Footnotes must be indicated with consecutive use of the following symbols: * † ‡ § ¶ || then 
** †† ‡‡ etc. 
  
Do not: Use [Enter] within a row to make ‘new rows’: 
  
Rather: 
Each row of data must have its own proper row: 
  
Do not: use separate columns for n and %: 
  
Rather: 
Combine into one column, n (%): 
  
Do not: have overlapping categories, e.g.: 
  
Rather: 
Use <> symbols or numbers that don’t overlap: 
  
  
References 
NB: Only complete, correctly formatted reference lists in Vancouver style will be 
accepted. Reference lists must be generated manually and not with the use of reference 
manager software. Endnotes must not be used. 
 Authors must verify references from original sources. 
 Citations should be inserted in the text as superscript numbers between square brackets, e.g. 
These regulations are endorsed by the World Health Organization,[2] and others.[3,4-6] 
 All references should be listed at the end of the article in numerical order of appearance in 
the Vancouver style (not alphabetical order). 
 Approved abbreviations of journal titles must be used; see the List of Journals in Index Medicus. 
 Names and initials of all authors should be given; if there are more than six authors, the first 
three names should be given followed by et al. 
 Volume and issue numbers should be given. 
 First and last page, in full, should be given e.g.: 1215-1217 not 1215-17. 
 Wherever possible, references must be accompanied by a digital object identifier (DOI) link). 
Authors are encouraged to use the DOI lookup service offered by CrossRef: 
o On the Crossref homepage, paste the article title into the ‘Metadata search’ box. 
o Look for the correct, matching article in the list of results. 
o Click Actions > Cite 
o Alongside 'url =' copy the URL between { }. 
o Provide as follows, e.g.: https://doi.org/10.7196/07294.937.98x 
  
Some examples: 
 Journal references: Price NC, Jacobs NN, Roberts DA, et al. Importance of asking about 
glaucoma. Stat Med 1998;289(1):350-355. http://dx.doi.org/10.1000/hgjr.182 
 Book references: Jeffcoate N. Principles of Gynaecology. 4th ed. London: Butterworth, 
1975:96-101. 
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 Chapter/section in a book: Weinstein L, Swartz MN. Pathogenic Properties of Invading 
Microorganisms. In: Sodeman WA, Sodeman WA, eds. Pathologic Physiology: Mechanisms of 
Disease. Philadelphia: WB Saunders, 1974:457-472. 
 Internet references: World Health Organization. The World Health Report 2002 - Reducing 
Risks, Promoting Healthy Life. Geneva: WHO, 2002. http://www.who.int/whr/2002 (accessed 
16 January 2010). 
 Legal references 
•              Government Gazettes: 
National Department of Health, South Africa. National Policy for Health Act, 1990 (Act No. 
116 of 1990). Free primary health care services. Government Gazette No. 17507:1514. 
1996. 
In this example, 17507 is the Gazette Number. This is followed by :1514 - this is the notice 
number in this Gazette. 
•              Provincial Gazettes: 
Gauteng Province, South Africa; Department of Agriculture, Conservation, Environment and 
Land Affairs. Publication of the Gauteng health care waste management draft regulations. 
Gauteng Provincial Gazette No. 373:3003, 2003. 
•              Acts: 
South Africa. National Health Act No. 61 of 2003. 
•              Regulations to an Act: 
South Africa. National Health Act of 2003. Regulations: Rendering of clinical forensic 
medicine services. Government Gazette No. 35099, 2012. (Published under Government 
Notice R176). 
•              Bills: 
South Africa. Traditional Health Practitioners Bill, No. B66B-2003, 2006. 
•              Green/white papers: 
South Africa. Department of Health Green Paper: National Health Insurance in South Africa. 
2011. 
•              Case law: 
Rex v Jopp and Another 1949 (4) SA 11 (N) 
Rex v Jopp and Another:  Name of the parties concerned 
1949: Date of decision (or when the case was heard) 
(4): Volume number 
SA: SA Law Reports 
11: Page or section number 
(N): In this case Natal - where the case was heard. Similarly, (C) woud indicate Cape, (G) 
Gauteng, and so on. 
NOTE: no . after the v 
 Other references (e.g. reports) should follow the same format: Author(s). Title. Publisher 
place: Publisher name, year; pages. 
 Cited manuscripts that have been accepted but not yet published can be included as 
references followed by '(in press)'. 
 Unpublished observations and personal communications in the text must not appear in the 
reference list. The full name of the source person must be provided for personal 
communications e.g. '...(Prof. Michael Jones, personal communication)'. 
  
From submission to acceptance 
83
Submission and peer-review 
To submit an article: 
 Please ensure that you have prepared your manuscript in line with the SAMJ requirements. 
 All submissions should be submitted via Editorial Manager 
 The following are required for your submission to be complete: 
o Anonymous manuscript (unless otherwise stated) 
o Author Agreement form 
o Manuscript 
o Any supplementary files: figures, datasets, patient consent form, permissions for published 
images, etc. 
 Once the submission has been successfully processed on Editorial Manager, it will undergo a 
technical check by the Editorial Office before it will be assigned to an editor who will handle 
the review process. If the author guidelines have not been appropriately followed, the 
manuscript may be sent back to the author for correcting. 
  
Peer-review process 
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Production process 
The following process should usually take between 4 - 6 weeks: 
1. An accepted manuscript is passed to a Managing Editor to assign to a copyeditor (CE). 
2. The CE copyedits in Word, working on house style, format, 
spelling/grammar/punctuation, sense and consistency, and preparation for 
typesetting. 
3. If the CE has an author queries, he/she will contact the corresponding author and 
send them the copyedited Word doc, asking them to solve the queries by means of 
track changes or comment boxes. 
4. The authors are typically asked to respond within 1-3 days. Any comments/changes 
must be clearly indicated e.g. by means of track changes. Do not work in the original 
manuscript - work in the copyedited file sent to you and make your changes clear. 
5. The CE will finalise the article and then it will be typeset. 
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6. Once typeset, the CE will send a PDF of the file to the authors to complete their final 
check, while simultaneously sending to the 2nd-eye proofreader. 
7. The authors are typically asked to complete their final check and sign-off within 1-2 
days. No major additional changes can be accommodated at this point. 
8. The CE implements the authors’ and proofreader’s mark-ups, finalises the file, and 
prepares it for the upcoming issue. 
  
Changing contact details or authorship 
Please notify the Editorial Department of any contact detail changes, including email, to 
facilitate communication. 
  
  
Publication 
Online v. print 
The SAMJ is an online journal. The online version of the journal is the one that has the 
widest circulation, is indexed by bibliographic databases including PubMed and SciELO, and 
is accessible in academic libraries. A printed edition , containing material selected by the 
Editor is also published each month and distributed to the membership of the South African 
Medical Association. 
  
  
Online 
 The full text of all accepted articles is published in full online, open access, within 4 - 6 weeks 
of acceptance. 
 Citation information of each article is based on its online publication. 
 You may want to make use of the advantages of online publication e.g. specify web links to 
other sources, images, data or even a short video. 
  
Print 
 Not all articles will be selected for print. 
 An article may be selected for print in a different month from that in which it was published 
online. 
 Research articles will appear in abstract form only, if selected for a print edition. 
  
Errata and retractions 
Errata 
Should you become aware of an error or inaccuracy in yours or someone else’s contribution 
after it has been published, please inform us as soon as possible via an email to 
publishing@hmpg.co.za,including the following details: 
 Journal, volume and issue in which published 
 Article title and authors 
 Description of error and details of where it appears in the published article 
 Full detail of proposed correction and rationale 
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We will investigate the issue and provide feedback. If appropriate, we will correct the web 
version immediately, and will publish anerratum  in the next issue. The correction will be 
indexed, as PubMed has a function for linking errata back to the original article. All 
investigations will be conducted in accordance with guidelines provided by the Committee on 
Publication Ethics (COPE). 
  
Retractions 
Retraction of an article is the prerogative of either the original authors or the editorial team 
of HMPG. Should you wish to withdraw your article before publication, we need a signed 
statement from all the authors. 
  
Should you wish to retract your published article, all authors have to agree in writing before 
publication of the retraction. 
Send an email to publishing@hmpg.co.za, including the following details: 
 Journal, volume and issue to which article was submitted/in which article was published 
 Article title and authors 
 Description of reason for withdrawal/retraction. 
  
We will make a decision on a case-by-case basis upon review by the editorial committee in 
line with international best practices. Comprehensive feedback will be communicated with 
the authors with regard to the process. In case where there is any suspected fraud or 
professional misconduct, we will follow due process as recommended by the Committee on 
Publication Ethics (COPE), and in liaison with any relevant institutions. 
  
When a retraction is published, it will be linked to the original article. 
  
Indexing 
The SAMJ has an impact factor of 1.5. 
Published articles are covered by the following major indexing services. As such articles 
published in the SAMJ are immediately available to all users of these databases, guaranteed 
a global and African audience: 
 Index Medicus (Medline/PubMed)  
 ExcerptaMedica (EMBASE) 
 Biological Abstracts (BIOSIS) 
 Science Citation Index (SciSearch) 
 Current Contents/Clinical Medicine 
 Scopus 
 AIM 
 AJOL 
 Crossref 
 Sabinet 
 Scielo 
  
Sponsored supplements 
Contact claudian@hmpg.co.za for information on submitting ad hoc/commissioned 
supplements, including guidelines, conference/congress abstracts, Festschrifts, etc. 
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Submission Preparation Checklist 
As part of the submission process, authors are required to check off their submission's 
compliance with all of the following items, and submissions may be returned to authors that 
do not adhere to these guidelines. 
1. Named authors consent to publication and meet the requirements of authorship as set 
out by the journal. 
2. The submission has not been previously published, nor is it before another journal for 
consideration. 
3. The text complies with the stylistic and bibliographic requirements in Author 
Guidelines. 
4. The manuscript is in Microsoft Word document format. The text is single-spaced, in 
12-point Times New Roman font, and contains no unnecessary formatting. 
5. Illustrations/figures are high resolution/quality (not compressed) and in an acceptable 
format (PDF or jpeg). These must be submitted individually as 'supplementary files' 
(not solely embedded in the manuscript). 
6. For illustrations/figures or tables that have been published elsewhere, the author has 
obtained written consent to republication from the copyright holder. 
7. Where possible, references are accompanied by a digital object identifier (DOI). 
8. An abstract has been included where applicable. 
9. The research was approved by a Research Ethics Committee (if applicable) 
10. Any conflict of interest (or competing interests) is indicated by the author(s). 
  
Copyright Notice 
Copyright of published material remains in the Authors’ name. This allows authors to use 
their work for their own non-commercial purposes without seeking permission from the 
Publisher, subject to properly acknowledging the Journal as the original place of publication. 
 Authors are free to copy, print and distribute their articles, in full or in part, for teaching 
activities, and to deposit or include their work in their own personal or institutional database 
or on-line website. Authors are requested to inform the Journal/Publishers of their 
desire/intention to include their work in a thesis or dissertation or to republish their work in 
any derivative form (but not for commercial use).  
 Material submitted for publication in the SAMJ is accepted provided it has not been 
published or submitted for publication elsewhere. Please inform the editorial team if the 
main findings of your paper have been presented at a conference and published in abstract 
form, to avoid copyright infringement. 
  
Privacy Statement 
The SAMJ is committed to protecting the privacy of the users of this journal website. The 
names, personal particulars and email addresses entered in this website will be used only 
for the stated purposes of this journal and will not be made available to third parties without 
the user’s permission or due process. Users consent to receive communication from 
the SAMJ for the stated purposes of the journal. Queries with regard to privacy may be 
directed to publishing@hmpg.co.za. 
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